



Rheumatology

2013

23-25 April | Birmingham, UK

**Your INVITATION to
Rheumatology 2013**
**Where the rheumatology
community meets**

BOOK NOW!

**“Probably the best
national conference
in the world”**

Early bird registration deadline: Friday 1 February 2013

Join Your colleagues at **Rheumatology**



Your **INVITATION** . . .

We do hope that you are planning to join us at **Rheumatology 2013** in Birmingham. The conference is the UK's leading rheumatology event and offers an invaluable chance for colleagues to come together to learn, network and hear about the latest developments in the field.



We are all working in an increasingly challenging environment and so it is more important than ever that we come together as a community to support each other and raise the profile of specialty.

We hope to see you in Birmingham,

Dr Chris Deighton and Mr Robert Field

What people thought about Rheumatology 2012

95% of delegates would recommend the conference to a colleague

91% say the conference is a key date in their professional calendar

95% of delegates learnt something new

75% of doctors/allied health professionals would change their practice following the conference

Key INFORMATION . . .

Rheumatology 2013 is focused on best practice in rheumatology. Sessions are designed with clear aims and outcomes, leading to effective and valuable learning opportunities for the whole rheumatology team

WHY attend?

- A must for **continuing professional development**
- Innovative, engaging and **interactive sessions**
- Emphasis on **pioneering developments**
- Streamed sessions dedicated to **revalidation, trainees, allied health professionals** and **scientists**
- **Peer reviewed** oral and poster **abstracts**
- Superb **networking** opportunities
- Prestigious **keynote lectures**
- Renowned national and **international speakers**
- Updates on **commissioning** and **NHS changes**
- Comprehensive **exhibition**

WHO should attend?

Our varied conference programme appeals to all healthcare professionals with an interest in rheumatology:

- Consultant rheumatologists
- Researchers
- Doctors in training
- Scientists
- Nurse specialists
- Students
- GPs
- Occupational therapists
- Academics
- Podiatrists
- Physiotherapists
- Industry professionals

Venue

The ICC, Broad Street, Birmingham, B1 2EA

Rheumatology 2013 will be held at the ICC, in the centre of Birmingham, a vibrant city boasting excellent transport links to all parts of the UK and beyond.

Getting there

For full details of transport options, visit the ICC's website www.theicc.co.uk/locationtravel

Accommodation

Rheumatology 2013 delegates can use the services of our accommodation agents, HG3; to take advantage of specially negotiated room rates. We have secured an allocation at a variety of hotels across the city to suit all budgets. Early booking is highly recommended, bookings made after 1 April 2013 will be subject to availability and a higher price. Bookings can be made online via www.rheumatology.org.uk/accommodation

Don't forget to create your conference schedule

With so many high quality sessions on offer, make sure you make the most of your time at the conference with our online programme planner. View the details of the sessions on offer and build your own conference diary which you can then print off or email. Go to www.rheumatology.org.uk/programme to start planning your time at the UK's leading rheumatology conference.

Early bird registration deadline:
Friday 1 February 2013

Keynote SPEAKERS



Tuesday 23 April, 14:00 – 16:00

Keynote: Jewels in the crown

Mr Bob Ricketts, CBE, Director of NHS Provider Transition (Department of Health), Director of Commissioning support strategy and Market Development (NHS Commissioning Board)

Bob has held a succession of senior posts at the Department of Health, all associated with reform of health services, including patient choice, commissioning (including the NHS Standard Contract), and provision (including leading the Transforming Community Services programme and development of social enterprises in health and social care). He is currently both Director of Provider Transition for the Department of Health and Director of Commissioning Support Services Strategy and Market Development for the NHS Commissioning Board, and will take up the latter post full-time from April 2013. He has featured in the Health Service Journal 100 list of the people with the greatest influence on health policy and the NHS for the last 5 years. He was awarded a CBE in last year's New Year's Honours list.

His Interests outside work include local history and archaeology, UK postal history and Cairn Terriers.



Tuesday 23 April 16:30 – 17:30

Heberden Round

Prof Caroline Gordon, Professor of Rheumatology at the University of Birmingham and Consultant Rheumatologist at Sandwell and West Birmingham Hospitals NHS Trust and University Hospitals Birmingham NHS Foundation Trust

Caroline Gordon set up the Birmingham lupus cohort soon after her arrival in Birmingham as a clinical lecturer in 1989. She has undertaken clinical work and teaching as a consultant rheumatologist at City Hospital, Sandwell and West Birmingham Hospitals NHS Trust and the Queen Elizabeth Hospital, University Hospital Birmingham Foundation NHS Trust since 1996. She also has a clinic at Birmingham Women's Hospital for women with systemic rheumatic diseases (particularly lupus and anti-phospholipid syndrome but including severe rheumatoid arthritis, systemic sclerosis and vasculitis) in pregnancy and for those who need pre-pregnancy counseling. The Birmingham lupus clinics have been awarded the title of LUPUS UK Centre of Excellence since 2005, the first lupus centre in the UK to receive this award. Caroline Gordon was awarded the title of Professor of Rheumatology at the University of Birmingham in 2007.

Her research programme focuses on systemic lupus erythematosus but she has contributed to research in to inflammatory arthritis, vasculitis, Sjögren's syndrome and anti-phospholipid syndrome as well. Much of her work has focused on disease assessment for clinical trials and outcome studies, particularly the development of the BILAG disease activity index and the epidemiology of lupus. She has been involved in the development of the SLICC/ACR damage index and in the assessment of quality of life in lupus patients using the SF-36 and the Lupus QoL surveys. She has a longstanding interest in improving the treatment of systemic lupus erythematosus and has been involved in organising 3 investigator led trials. The 2 UK based trials were IV cyclophosphamide versus oral cyclophosphamide in lupus nephritis (EULAR sponsored) and cyclosporine versus azathioprine in severe SLE (Arthritis Research UK funded). She led the initiative producing EULAR points to consider for conducting clinical trials in SLE and advises the pharmaceutical industry on organising and analysing lupus clinical trials. She has been closely involved in the development of epratuzumab, an anti-CD22 targeted monoclonal antibody therapy for lupus. She has worked with Lupus UK and Lupus Europe as well as the NIHR to promote patient involvement in clinical trials. She is a consultant to the Centre for Disease Control on epidemiological studies of lupus in the USA, and to Lupus Foundation of America on their clinical trials training programme (POINT). Her other research interests include clinical and laboratory markers of disease flare, the importance of ethnicity in predicting disease susceptibility and long-term outcome, and the health of children born to mothers with lupus. She is a member of the British Isles Lupus Assessment Group (BILAG), the Systemic Lupus International Collaborating Clinics (SLICC), Co-Chair of the European League Against Rheumatism (EULAR) Task Force for Systemic Lupus Erythematosus and has been a member of several British Society for Rheumatology, American College of Rheumatology and Lupus Foundation of America committees for lupus research. She has been the lupus lead on the Arthritis Research UK systemic autoimmune disease clinical study group and Chair of the national Comprehensive Clinical Research Network (CCRN) Immunology and Inflammation Specialty Group for the National Institute for Health Research (NIHR) since 2008.



Wednesday 24 April 16:30 – 17:30
Heberden Oration

Prof Paul Emery, Arthritis Research UK Professor of Rheumatology, Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Director, Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust

Professor Emery is the Arthritis Research UK Professor of Rheumatology and Head of the Academic Division of Rheumatic & Musculoskeletal Disease, University of Leeds and the Director of the Leeds Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust, U.K.

Professor Emery was President of EULAR 2009-2011, he is currently Past President. He has served on the editorial boards of all the major rheumatology journals. He was inaugural President of ISEMIR (International extremity MRI society). He is an NIHR Senior Investigator. He is a recipient of the Roche Biennial Award for Clinical Rheumatology; the Rheumatology Hospital Doctor of the Year award 1999; and EULAR prize 2002 for outstanding contribution to rheumatology research. In 2012 he was awarded the Carol Nachman Prize.

Professor Emery's research interests centre around the immunopathogenesis and immunotherapy of rheumatoid arthritis, SpA and connective tissue diseases. He has a special interest in the factors leading to persistent inflammation. He has published over 800 peer-reviewed articles in this area.



Thursday 25 April, 11:30 – 13:00
Droitwich Lecture

Dr Philip Helliwell, Senior Lecturer in Rheumatology at the University of Leeds and Honorary Consultant Rheumatologist for the Bradford Hospitals NHS Trust

Dr Helliwell is co-founder and co-lead for the Bradford (University) Diploma in Rheumatology and Musculoskeletal

Medicine and is an active member of the Bradford and Airedale Musculoskeletal Alliance, a tier two service provided to GPs in the designated geographical area.

His previous and current appointments include: Member of NHS R&D Research Committee on Physical and Complex Disabilities, Member of the Executive Council, Centre for Biomechanics and Medical Engineering; Treasurer and Member of Executive Committee, Society for Back Pain Research; Member of Education Committee, Arthritis Research Campaign; and Editor for the ARC Patient Information Leaflets and Convener Publications Working Group, Member of the Heberden Committee, at the British Society

for Rheumatology, Member of Council at the British Society for Rheumatology, Member of Executive Committee, Group for Research and Assessment of Psoriasis and Psoriatic arthritis.

His current and past research: treatment paradigms, clinical features and classification of psoriatic arthritis; biomechanics of joints, gait assessment and foot disorders in inflammatory and non-inflammatory arthritis, epidemiology of rheumatic disease with a longitudinal community cohort of low back pain and community based studies of psoriasis and psoriatic arthritis



Thursday 25 April, 14:00 – 15:30
Commissioning in a cold climate

Prof Paul Corrigan, Former Senior Health Policy Adviser to the Prime Minister Tony Blair and Former Director of Strategy and Commissioning at the London Strategic Health Authority

Paul Corrigan gained his first degree in social policy from the LSE in 1969, his PhD at Durham in 1974. He is currently adjunct professor of public health at the Chinese University of Hong Kong and of health policy and Imperial College London.

For the first 12 years of his working life he taught at Warwick University and the Polytechnic of North London. During this period he taught, researched and wrote about inner city social policy and community development. In 1985 he left academic life and became a senior manager in London local government and in 1997 he started to work as a public services management consultant. In 1998 he published Shakespeare on Management.

From July 2001 he worked as a special adviser to Alan Milburn first and then John Reid, the then Secretary of States for Health. At the end of 2005 he became the senior health policy adviser to the Prime Minister Tony Blair. Over this six years he was instrumental in developing all the major themes of NHS reform not only in terms of policy levers but also in developing capacity throughout the NHS to use those levers.

Between June 2007 and March 2009 he was the director of strategy and commissioning at the London Strategic Health Authority.

Since then Paul has been working as a management consultant and an executive coach helping leaders within the NHS create and develop step changes within their organisation. In September 2011 he published a pamphlet "The hospital is dead Long live the Hospital" that was recognised by a leader in the Times as an important contribution to reform. As a columnist for the Health Service Journal he has continued to argue the case for NHS reform. He has an influential blog "Health Matters" that develops these issues.

TUESDAY 23 APRIL 2013

09.00 – 10.30

- Faster, safer, cheaper? Advances in orthopaedic science
- An embarrassment of riches: clinical research in rheumatoid arthritis
- BHPR: The experience of living with musculoskeletal problems and other conditions
- New insights on the pathogenesis and treatment of crystal arthritis
- Oral abstracts: Connective tissue disease
- SIG: Spondyloarthropathy
- BHPR SIG: Connective tissue disease

10.30 – 11.30 Poster viewing and exhibition | Tea and coffee

11.30 – 13.00

- BHPR: Interactive panel discussion and problem solving to optimise work participation
- BSR/BHPR: Facilitating adherence to treatment in rheumatology
- Osteoporosis: an update
- Biologics in connective tissue disease
- Oral abstracts: Pathogenesis
- SIG: Musculoskeletal pain
- SIG: Foot and ankle

13.00 – 14.00 Exhibition | Lunch

13.00 – 14.00

- BSR/BHPR: Post graduate research student network
- Register open meeting

14.00 – 16.00

- **Jewels in the Crown**
Within the prestigious Jewels in the Crown plenary session, chaired by the presidents of BSR and BHPR, we will be showcasing the top scoring abstracts and awarding the Michael Mason and Garrod Prize winners.

16.00 – 16.30 Exhibition | Tea and Coffee

16.30 – 17.30

- Heberden Round

17.30 – 19.15

- Industry supported symposia (including catering): Roche

19.30 – 21.30

- Presidents' reception

"A priceless opportunity to learn, share experience and reflect. It has changed my concept about various aspects of modern rheumatology, and subsequently my practice has been changed"

"Probably the best national conference in the world - focussed, informative and not so large that one misses out because of sessional conflicts"

"The conference is a must for rheumatology nurse specialists, excellent updates and networking"

* Correct at the time of printing, but is subject to change.

WEDNESDAY 24 APRIL 2013

07.00 – 08.30

- Industry supported symposia (including catering): Actelion
- Industry supported symposia (including catering): Pfizer

09.00 – 10.30

- BHPR: Are our interventions cost-effective?
- BHPR: Measuring disease activity in RA, when your patient is in remission
- Essentials in rheumatology: Disease management
- Managing the care gap: implementing evidence-based practice in primary care
- Ultrasound: what is in it for you?
- Getting to grips with the use of social media tools in rheumatology
- Oral abstracts: Adolescent and young adult
- SIG: Education

10.30 – 11.30 Poster viewing and exhibition | Tea and coffee

11.30 – 13.00

- Musculoskeletal clinical networks in the new NHS landscape
- Arthritis pain: mechanisms, meaning and medicines
- Essentials in rheumatology: Symptoms diagnosis and management
- The emerging role of epigenetics in rheumatic diseases
- BHPR plenary orals
- Oral abstracts: Primary care
- SIG: MSK disorders in ethnic minorities
- SIG: Adolescent and young adult
- SIG: Ultrasound

13.00 – 14.30 Exhibition | Lunch

13.00 – 14.30

- BSR AGM

16.00 – 16.30 Exhibition | Tea and Coffee

14.30 – 16.00

- Adolescent and young adult
- BHPR: Clinical update on axial spondyloarthropathy (ASpA)
- BHPR: Measuring disease activity in psoriatic arthritis
- BSR/BHPR: Longstanding musculoskeletal pain: impact, perceptual representations and treatment
- Essentials in rheumatology: Clinical decision making
- Oral abstracts: OA and metabolic bone disease
- ARMA
- SIG: SLE

16.30 – 17.30

- Heberden Oration

17.30 – 19.15

- Industry supported symposia (including catering): Abbott

19.30 – Late

- Conference dinner

"The conference is invaluable for networking and forming collaborations for future research"

"Excellent trainee sessions"

"This is the conference to attend to update your knowledge no matter what level you work at in the field of rheumatology"

THURSDAY 25 APRIL 2013

07.00 – 08.30

- Industry supported symposia (including catering): Bristol-Myers Squibb

09.00 – 10.30

- Ageing and the musculoskeletal system
- Ask the experts
- BSR/BHPR: Advanced practice in osteoarthritis
- Mortality in rheumatic disease
- BHPR: Introducing cognitive behavioural approaches to rheumatic disease: top tips and tools for clinic
- Oral abstracts: RA Clinical
- SIG: Heritable disorders of connective tissue
- SIG: Sjögren's

10.30 – 11.30 Poster viewing and exhibition | Tea and coffee

11.30 – 13.00

- Droitwich
- Polymyalgia rheumatic and giant cell arthritis
- Interactive clinical teaching: osteoporosis
- Oral abstracts: Genetics
- Oral abstracts: Science
- SIG: Scleroderma
- SIG: Soft tissue rheumatism and sports medicine

13.00 – 14.30 Exhibition | Lunch

13.00 – 14.00

- BHPR AGM
- RATs AGM
- Standards, audit and guidelines working group open meeting

14.00 – 15.30

- Advances in cartilage biology: towards a better understanding of osteoarthritis
- BHPR: The use of ultrasound for nurses and allied health professionals
- Career development for new consultants
- Commissioning session
- BHPR: The importance of health literacy in musculoskeletal disease
- Oral abstracts: Spondyloarthritis
- SIG: Myositis
- SIG: Rheumatoid arthritis

16.00 – 17.30

- SIG: Genetics
- SIG: Osteoarthritis arthritis
- SIG: RA outcomes
- SIG: Vasculitis
- SIG: Interstitial lung disease

17.30 Meeting Close

Poster tours

Tuesday 23 April 2013 | 10.30 – 11.30

Poster Tours

RA clinical
RA pathogenesis
Case reports

Wednesday 24 April 2013 | 10.30 – 11.30

Poster Tours

BHPR
SLE and antiphospholipid syndrome
Education

Thursday 25 April 2013 | 10.30 – 11.30

Poster Tours

Epidemiology
Connective tissue disease
Spondyloarthritis

"I found it very stimulating and I learned things that will change my practice"

"A first-rate conference that is a must for all who treat patients with rheumatological conditions"

KEY

SESSION | BHPR

BSR/BHPR JOINT SESSION

PRIMARY CARE

ESSENTIALS IN RHEUMATOLOGY

SCIENCE STREAM | TRAINEE STREAM

KEYNOTE SESSION | ORAL ABSTRACTS

SPECIAL INTEREST GROUPS

INDUSTRY SUPPORTED SYMPOSIUM

NETWORKING



09.00 – 10.30

New insights on the pathogenesis and treatment of crystal arthritis

Chairs: Dr Edward Roddy, Arthritis Research UK, Keele University, Keele and Prof George Nuki, University of Edinburgh, Edinburgh

Aim:

Provide an update on the causes and optimal treatments of common crystal arthropathies

Outcome 1:

Understand the genetic and environmental risk factors for crystal arthritis

Outcome 2:

Understand the potential importance of treating to target for gout

Outcome 3:

Update on existing and new therapeutic options

09.00

Gout: should we treat to target?

Prof Pascal Richette, Université Paris 7, Paris, France

09.30

Pathogenesis and treatment of pyrophosphate arthropathy

Prof Geraldine McCarthy, Mater Misericordiae University Hospital, Dublin, Ireland

10.00

Genetic and environmental risk for hyperuricaemia and gout

Prof Michael Doherty, University of Nottingham, Nottingham

09.00 – 10.30

Faster, safer, cheaper? Advances in orthopaedic science

Chairs: Dr Fraser Birrell, University of Newcastle, Newcastle and Prof George Peat, Keele University, Keele

Aim:

Joint surgery is undergoing a scientific revolution, with dogma being replaced by evidence based practice. The aim of this session is to highlight some key advances:

Outcome 1:

Delegates will know about the introduction of fast track surgery (which has reduced complication rates)

Outcome 2:

Delegates will understand the National Joint registry (which has guided use of particular implants), and the shift in focus towards Patient Reported Outcome Measure (PROMS)

Outcome 3:

Delegates will recognise the problems with resurfacing procedures

09.00

Fast-track hip and knee arthroplasty: current status and future challenges

Mr Henrik Husted, Hvidovre University Hospital, Hvidovre, Denmark

09.25

Lessons from the national joint registry and patient reported outcome measures (PROMS)

Mr Simon Jameson, National Joint Registry, Middlesbrough

09.50

Insights into hip resurfacing and what happened with metal on metal implants

Mr Mike Reed, Northumbria Healthcare NHS Foundation Trust, Ashington

10.15

Panel Discussion

09.00 – 10.30

An embarrassment of riches: clinical research in rheumatoid arthritis

Chair: Prof John Isaacs, University of Newcastle, Newcastle

Aim:

To highlight the patient benefits of research involvement, and to raise the notion that recruitment of patients into research should be considered a 'quality measure'

Outcome 1:

To demonstrate patient benefits of involvement in clinical research

Outcome 2:

To highlight, contrast and raise awareness of the wide variety of research opportunities for RA patients

Outcome 3:

To stimulate debate around distinct research opportunities – is a phase III pharmaceutical industry trial better for my patients than a phase I experimental medicine study? Should economic considerations influence my decision? Should trial recruitment become an auditable quality measure for rheumatologists?

09.00

How clinical research improves patient outcomes

Dr A Murray Brunt, University Hospital of North Staffordshire, Stoke-on-Trent

09.15

How research changed my life

Mrs Ailsa Bosworth, NRAS - National Rheumatoid Arthritis Society, Berkshire

09.30

Should it be standard of care to offer entry to research trials at each therapeutic decision stage of the patient journey?

Dr Maya Buch, University of Leeds, Leeds

09.45

Research opportunities for the RA patient, their rheumatologist, and their AHP, including economic aspects

Prof Deborah Symmons, University of Manchester, Manchester

10.00

Recruitment of RA patients into research should provide an auditable quality measure

Dr Peter Dawes, Haywood Hospital, Stoke-on-Trent and Dr Ian Rowe, Worcestershire Royal Hospital, Worcester

09.00 – 10.30

BHPR: The experience of living with musculoskeletal problems and other conditions

Chairs: Prof Bie Nio Ong, Keele University, Keele and Mrs Jenny Ratcliffe, East Cheshire NHS Trust, Macclesfield

Outcome 1:

To appreciate the complex nature of multimorbidity, in particular, that it can consist of many different combinations of conditions and thus result in a wide range of impacts on individuals' quality of life and their use of health care

Outcome 2:

Through discussion begin to formulate how health professionals can best respond to the complexity of multimorbidity

09.00

Multimorbidity, quality of care and self-management in patients with arthritis and long-term conditions: analyses from a prospective primary care cohort

Prof Peter Bower, University of Manchester, Manchester

09.15

The role of patients' social networks in shaping the experience of musculoskeletal conditions and multimorbidity

Mr Tom Porter, Keele University, Stoke-On-Trent, Keele

09.30

Do people with chronic musculoskeletal problems and multimorbidity set priorities?

Dr Sudeh Cheraghi-Sohi, Keele University, Keele

09.00 – 10.30

Oral abstracts: Connective tissue disease

09.00

Long-term outcomes of children born to mothers with SLE

Dr Mary Gayed, Sandwell and West Birmingham Hospitals, Birmingham

09.15

Higher corticosteroid doses early in disease have a long-term influence on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.

Dr Benjamin Parker, University of Manchester, Manchester

09.30

Simple insoles for managing foot problems in people with SSC: the Pisces randomized controlled trial

Dr Anthony Redmond, University of Leeds, Leeds

09.45

A retrospective study of long-term outcome in 152 patients with primary Sjögren's syndrome – 25 year experience

Ms Esha Abrol, University College London Medical School, London

10.00

Successful use of Tocilizumab in the treatment of refractory FDG pet positive large vessel vasculitis: a case series

Dr Sanam Kia, Southend Hospital, Southend-on-Sea

10.15

Factors associated with long-term damage in the ANCA-associated vasculitides: an analysis of cohorts from the European vasculitis study group (EUVAS) therapeutic trials

Dr Joanna Robson, University of Oxford, Oxford

09.00 – 10.30

SIG: Spondyloarthropathy

Chairs: Dr Raj Sengupta, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath and Prof Dennis McGonagle, University of Leeds, Leeds

Aim:

To increase awareness of advances in diagnosis, management, biomarkers and clinical trials in the field of spondyloarthritis

Outcome 1:

Attendees will understand the treatment of axial spondyloarthritis

Outcome 2:

Attendees will be updated on the current clinical trials in spondyloarthritis

Outcome 3:

Attendees will be updated on the role of biomarkers in diagnosing and assessing spondyloarthritides

09.00

Welcome and introduction

Prof Dennis McGonagle, University of Leeds, Leeds and Dr Raj Sengupta, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath

09.10

Treating non radiographic axial spondyloarthritis?

Dr Lesley Kay, University of Newcastle, Newcastle

09.30

Current clinical trials in AS

Dr Jon Packham, University Hospital of North Staffordshire, Staffordshire

09.50

Update on new biologics in PsA

Prof Dennis McGonagle, University of Leeds, Leeds

10.10

What is the best way to do clinical screening for PsA in dermatology setting

Dr Philip Helliwell, University of Leeds, Leeds

09.00 – 10.30

BHPR SIG: Connective tissue disease

Chair: Ms Sue Brown, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath

Aim:

To address musculoskeletal health in pregnancy and explore the role of the multi-disciplinary team

Outcome 1:

To give an overview of the important aspects of managing women in pregnancy and when to act on red flags

Outcome 2:

To consider the important role of physiotherapists and nurses in managing pregnancy in rheumatology

Outcome 3:

To provide information about medications that are safe to use in pregnancy and discuss some of the potential problems that may arise due to medication

09.00

Setting up a rheumatology pregnancy clinic

Dr Maddy Piper, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath

09.20

Pre-pregnancy counselling: the role of the nurse

Ms Sue Brown, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath

09.30

Physiotherapy interventions in managing musculoskeletal pain in pregnancy

Dr Yvonne Coldron, Croydon University Hospital, Croydon

10.10

Medications in pregnancy

Dr Mary Gayed, University of Birmingham, Birmingham

10.30 – 11.30

Poster viewing and exhibition | Tea and Coffee**Categories**

Case reports

Imaging

Metabolic and crystal arthropathies

Rheumatoid arthritis: pathogenesis and animal models

Rheumatoid arthritis: treatment

Rheumatoid arthritis: clinical features

Rheumatoid arthritis: comorbidities

Poster Tours

RA clinical

RA pathogenesis

Case reports

11.00 – 11.30

NEW – Innovation theatre: Roche

ANCA - associated vasculitis for rheumatologists

Speaker: Professor David Scott, Norfolk and Norwich University Hospital, Norwich

11.30 – 13.00

BSR/BHPR: Facilitating adherence to treatment in rheumatology*Chairs: Prof Anne Barton, University of Manchester, Manchester and Dr Claire Goodchild, King's College London, London***Aim:**

To provide clinicians with an overview of the patient factors that could affect adherence to treatment and how this information could be used to facilitate adherence

Outcome 1:

Attendees will understand some of the health beliefs which may impact on non-adherence to treatment

Outcome 2:

Attendees will understand some of the behaviour change strategies which may be employed in clinical practice to facilitate adherence to pharmacological and physical therapies

11.30

Patient non-adherence to treatment: what causes it and what can be done about it*Prof John Weinman, Institute of Psychiatry, London*

12.00

Adherence and adaptation: targeting beliefs and behaviour in optimising self management*Dr Lis Cordingley, University of Manchester, Manchester*

12.30

The clinical application of behaviour change strategies to facilitate adherence to treatment*Dr Sarah Dean, University of Exeter, Exeter*

11.30 – 13.00

Osteoporosis: an update*Chair: Dr Emma Clark, University of Bristol, Bristol***Aim:**

To provide general rheumatologists and trainees with an update on metabolic bone disease

Outcome 1:

To understand investigation and management of renal bone disease

Outcome 2:

To highlight the emerging idea of sarcopaenia and its importance to bone To discuss the role of drug holidays for bisphosphonates

Outcome 3:

To discuss the role of drug holidays for bisphosphonates

11.30

An update on investigation and management of renal bone disease*Prof David Hoskin, City Hospital, Nottingham*

12.00

Sarcopaenia: is it a disease and can it be treated?*Prof Avan Aihie Sayer, University of Southampton, Southampton*

12.30

Long-term treatment with bisphosphonates: what to do after five years?*Prof Juliet Compston, University of Cambridge, Cambridge*

11.30 – 13.00

Biologics in connective tissue disease*Chairs: Dr Hector Chinoy, University of Manchester, Manchester and Dr Benjamin Parker, University of Manchester, Manchester***Outcome 1:**

To discuss recent clinical trials of rituximab in ANCA-associated vasculitis

Outcome 2:

To review the use of available biologics in SLE and introduce emerging therapies

Outcome 3:

To review the use of novel biologic agents in severe haematological manifestations of CTD

11.30

Rituximab in ANCA-associated vasculitis*Dr Chetan Mukhtyar, Norfolk and Norwich University Hospital, Norwich*

12.00

Current and emerging biologics in SLE*Prof Ian Bruce, University of Manchester, Manchester*

12.30

Novel biologics in severe haematological manifestations of connective tissue disorders*Dr Jecko Thachil, Manchester Royal Infirmary, Manchester*

11.30 – 13.00

BHPR: Interactive panel discussion and problem solving to optimise work participation

Chairs: Dr Victoria Chamberlain, Trafford Healthcare NHS Trust, Manchester and Mr Federico Mosconi, ARMA, London

Aim:

To provide delegates with the opportunity to discuss ways to optimise work participation

Outcome 1:

To review the determinants of reduced work participation for adults with musculoskeletal conditions

Outcome 2:

To outline ways to reduce the barriers and improve work participation

Outcome 3:

To identify issues which need further review by clinicians and policy makers e.g. Department for Work and Pensions to improve work participation

11.30

Work and musculoskeletal conditions: the key issues

Dr Ross Wilkie, Keele University, Keele

11.45

Interactive panel discussion and problem solving to optimise work participation

Prof Dame Carol Black, Health and Work, London, Dr Bill Gunnyon, Department for Work and Pensions, London, Dr David Walker, Freeman Hospital, Newcastle and Ms Adele Higginbottom, Keele University, Keele

11.30 – 13.00

Oral abstracts: Pathogenesis

11.30

Characterising type 17 immune responses in ankylosing spondylitis

Dr Mohammad Hussein Al-Mossawi, Oxford University, Oxford

11.45

Synovial lymphocyte aggregates in early inflammatory arthritis: correlation with diagnosis, disease activity and antibody status

Dr Maria Di Cicco, Queen Mary University of London, London

12.00

Early treatment-naïve rheumatoid arthritis (RA) is characterised by qualitative changes of the INKT regulatory cell repertoire

Prof Stephan Gadola, University of Southampton and UHS NHS Foundation Trust, Southampton

12.15

Widespread citrullination in healthy and inflamed lung tissue as a priming site for autoimmunity in RA

Dr Elena Lugli, Kennedy Institute of Rheumatology, London

12.30

How does PTPN22 regulate T cell effector responses in inflammatory arthritis?

Dr Cristina Sanchez-Blanco, King's College London, London

12.45

Clinical significance of IL-6 and CCL2 upregulation in serum and renal biopsies from cases of scleroderma renal crisis

Dr Cassandra Hong, King's College Hospital, London

11.30 – 13.00

SIG: Musculoskeletal pain

Chair: Dr Nicholas Shenker, Cambridge University Hospitals, Cambridgeshire

Aim:

Engagement for members to understand and develop commissioning for musculoskeletal pain services; opportunity for clinical research studies to be discussed, from inception through to delivery; plan for the future of the MSK pain SIG

Outcome 1:

To be able to understand what projects are currently being developed and what clinical trials have come to fruition from the Arthritis Research UK pain study group. To understand the process of how to engage with this and take forward ideas

Outcome 2:

To be able to understand the commissioning environment. To be able to come up to date with the national pathways that have been developed as part of the British Pain Society's endeavours working with the Department of Health

Outcome 3:

To engage with the SIG members of what they would want a SIG to include, whether that be audits, surveys, support or newsletters. To request for volunteers who wish to be included in this to commit time and resources as necessary

11.30

Arthritis Research UK's Musculoskeletal pain study group: current trials and how to get involved

Prof Elaine Hay, Keele University, Keele

12.00

The commissioning climate for musculoskeletal pain services

Dr Benjamin Ellis, King's College Hospital, London

12.30

Musculoskeletal Pain SIG: what do we want from it?

Dr Nicholas Shenker, Cambridge University Hospitals, Cambridge

11.30 – 13.00

SIG: Foot and ankle

Chair: Dr Anthony Redmond, University of Leeds, Leeds

Aim:

The session will focus on gout, the arthritis most typically characterised by foot involvement. Delegates will be updated about how and why gout affects the foot and the emerging role of ultrasound for assessing joint involvement in gout

Outcome 1:

Delegates will gain knowledge of how the foot is affected by gout, both in the acute attack and chronically

Outcome 2:

Delegates will understand the pathophysiological mechanisms underlying the predilection of gout for the joints of the foot

Outcome 3:

Delegates will appreciate the potential role of ultrasound in the diagnosis and assessment of gout

11.30

Gout and the foot: a clinical overview

Dr Kristin Kay Willits Jordan, Brighton and Sussex University Hospitals, Brighton

11.50

The role of footwear in gout

Prof Keith Rome, Auckland University of Technology, Auckland, New Zealand

12.10

Why does gout target the foot: a critical role for osteoarthritis?

Dr Edward Roddy, Arthritis Research UK Primary Care Centre, Keele

12.30

Ultrasound assessment of the foot in gout

Prof Pascal Richette, Université Paris 7, Paris, France

13.00 – 14.00

Exhibition | Lunch

13.00 – 13.30

NEW – Innovation theatre: Abbott

State of the art ultrasound imaging: in your clinical practice

Speaker: Dr Cristina Estrach, Aintree University Hospitals NHS Foundation Trust, Liverpool

13.30 – 14.00

NEW – Innovation theatre: Savient

Speaker: To be announced

13.00 – 14.00

Registers open meeting

Aim:

To inform all those wanting to understand the implications of Register Research for their practice

Outcome 1:

Update members on the latest results and analysis from the RA and AS registers

Outcome 2:

Update the membership on the how to recruit and how to access data from the registries for audit and research

Outcome 3:

Provide insight into how the registers will develop in the coming years with the advent of electronic data entry

Open to all with an interest in the Biologics Registers, whether as a contributor of patient data or as a researcher interested in accessing the data. There will be an update of the latest news on recruitment and research



13.00 – 14.00

BSR/BHPR: Post graduate research student network

Chairs: Dr Annette Bishop, Arthritis Research UK, Keele University, Keele and Prof Sarah Hewlett, University of the West of England, Bristol

Aim:

To provide a coordinated network for early career researchers that facilitates peer group discussion and support from a range of leading academics

Outcome 1:

Attendees will participate in a structured networking event with different seniority levels of researchers to find common interests and build future collaborations

Outcome 2:

Attendees will practice effectively communicating their current research study

Outcome 3:

Attendees will contribute to a networking database that will be circulated after the event to enable contacts to become established

13.00

Introduction

Prof Sarah Hewlett, University of the West of England, Bristol

13.05

Planning your elevator pitch

Dr Caroline Flurey, University of the West of England, Bristol

13.10

Structured 'speed dating' educational networking facilitated by academics

Dr Caroline Flurey, University of West of England, Bristol and Prof Sarah Hewlett, University of West of England, Bristol

14.00 – 16.00

Jewels in the crown

Chairs: Dr Chris Deighton, President BSR and Mr Robert Field, President BHPR

14.00

Introduction

Dr Chris Deighton, President BSR and Mr Robert Field, President BHPR

14.05

The new commissioning landscape: opportunities and challenges

Mr Bob Ricketts, Director of NHS Provider Transition (Department of Health) and Director of Commissioning Support Strategy and Market Development (NHS Commissioning Board), London

14.40

Michael Mason prize winner: Dr Nidhi Sofat, St George's University of London, London

14.55

Garrod prize winner: Dr Charis Pericleous, University College London, London

15.10

Randomised controlled trial of tumour-necrosis-factor inhibitors (TNFi's) against combination intensive therapy with conventional disease modifying anti-rheumatic drugs (cDMARDs) in established rheumatoid arthritis (RA): the TACIT trial

Prof David Scott, King's College London, London

15.25

Epigenetic regulation of the IL23R locus in ankylosing spondylitis

Dr Carla Cohen, University of Oxford, Oxford

15.40

SARAH: strengthening and stretching for people with rheumatoid arthritis of the hands: a randomised controlled trial

Dr Mark Williams, University of Warwick, Coventry

16.00 – 16.30

Exhibition | Tea and coffee

16.30 – 17.30

Heberden Round

Prof Caroline Gordon, University of Birmingham, Birmingham

17.30 – 17.45

Industry supported symposia catering

17.45 – 19.30

Industry supported symposia: Roche

Challenging Expectations in RA Outcomes: Disease remission is achievable for patients on therapy without Methotrexate

Chair: Prof Ernest Choy, University of Cardiff, Cardiff

Welcome and introduction**Presenting the case: patients who cannot take MTX**

Prof Ernest Choy, University of Cardiff, Cardiff

Assessing the evidence: patients who cannot take MTX

Speaker to be announced

Assessing the evidence: remission versus response

Speaker to be announced

Assessing the evidence: safety of biologic therapy without MTX

Speaker to be announced

Question and Answer session

Panel

Summary and Close

Prof Ernest Choy, University of Cardiff, Cardiff

19.30 – 21.30

President's reception

The presidents of BSR and BHPR invite you to join them at this dedicated networking event at the nearby Birmingham Town Hall, which will provide the perfect opportunity to meet and continue your discussions with rheumatology colleagues and industry peers in a relaxed and informal setting

Drinks and canapés will be provided | This event is free to attend for registered delegates



07.00 – 07.30

Industry supported symposia catering

07.30 – 08.30

Industry supported symposia: Actelion

Digital Ulcers (DU) as a complication of Systemic Scleroderma (SSc): Management and prevention strategies and the importance of measuring outcomes

Chair: Prof Chris Denton, University College Medical School, London

Aim:

To provide delegates with up-to-date information on management strategies for DU patients and to discuss the importance of measuring outcomes in treatment success

Format: Six-physician panel to discuss the optimal management and latest recommendations in the treatment of DU patients. This is an interactive session for delegates with the use of voting keypads.

Outcome 1:

Delegates will be able to understand DU as a complication of SSc

Outcome 2:

Delegates will be able to understand optimal multidisciplinary management strategies in SSc and the importance of measuring outcomes

Outcome 3:

Delegates will be able to understand the importance of a preventative approach to DU management

Panel to be confirmed

07.00 – 07.30

Industry supported symposia catering

07.30 – 08.30

Industry supported symposia: Pfizer

09.00 – 10.30

Essentials in rheumatology: Disease management

Chairs: Prof John Axford, London Rheumatology Clinic, London and Dr Charles Mackworth-Young, Imperial College, London

Aim:

A comprehensive update covering everything you need to know about changes in rheumatology

Outcome 1:

To prepare rheumatologists for revalidation and provide a valuable educational opportunity for trainees

Outcome 2:

Delegates will have been brought up to date on disease management

09.00

Recognition and management of the auto-inflammatory diseases

Prof Dennis McGonagle, University of Leeds, Leeds

09.30

CFS and Fibromyalgia

Dr Frank McKenna, Central Manchester University Hospitals NHS Foundation Trust, Manchester

10.00

Sarcoidosis

Dr Toby Maher, Imperial College London, London

09.00 – 10.30

Getting to grips with the use of social media tools in rheumatology

Chair: Dr Raj Sengupta, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath

Aim:

To provide an overview of the potential use of new media to enhance communication in our practice of rheumatology

Outcome 1:

Delegates will be aware of the potential of social media to help clinicians improve communication with patients and colleagues including GPs and allied health professionals

Outcome 2:

Delegates will be aware of eLearning tools used to enhance education and know how they can contribute to the creation of educational material in new formats

Outcome 3:

Delegates will be aware of how to plan and manage their online 'presence', mindful of professional issues

09.00

How to learn using social media technologies

Dr Ronan Kavanagh, Bon Secours Hospital, Galway, Ireland

09.30

Social media and academia

Dr Anne-Marie Cunningham, University of Cardiff, Cardiff

10.00

Connecting with charities and patients using social media

Dr Martin Lee, Freeman Hospital, Newcastle

09.00 – 10.30

Ultrasound: what is in it for you?

Chairs: Dr Zunaid Karim, Midyorkshire NHS Trust, Pontefract and Prof Peter Taylor, University of Oxford, Oxford

Aim:

To provide rheumatologists with an outline of how using ultrasound can improve the care they offer to patients for each of the lecture

Outcome 1:

Delegates will be aware of the role ultrasound has played in improving the understanding and management of conditions discussed

Outcome 2:

Delegates will be able to recognise clinical situations where ultrasound is likely to benefit care Delegates will have a better understanding of current and future ultrasound research with potential future role

09.00

Ultrasound in rheumatoid arthritis

Dr Richard Wakefield, Chapel Allerton Hospital, Leeds

09.30

Ultrasound in spondyloarthropathy

Prof David Kane, Adelaide and Meath Hospital, Dublin, Ireland

10.00

Ultrasound in vasculitis

Prof Wolfgang Schmidt, Medical Centre for Rheumatology, Berlin, Germany

09.00 – 10.30

BHPR: Are our interventions cost-effective?

Chairs: Dr Martyn Lewis, Arthritis Research UK, Keele University, Keele and Dr Lindsay Bearne, King's College London, London

Aim:

To provide an overview of health economics and cost-evaluation of interventions provided by health professionals in rheumatology

Outcome 1:

Delegates will be aware of basic concepts of health economics in the context of health and healthcare and how this influences policy

Outcome 2:

Delegates will have an increased awareness of the need for cost-evaluation of their interventions and the main types of cost-evaluation in healthcare

Outcome 3:

Delegates will have a better understanding of current and future ultrasound research with potential future role

09.00

Considerations for health economics analysis in rheumatology

Dr Tracey Young, University of Sheffield, Sheffield

09.30

The cost-effectiveness of nurse-led care in people with RA

Dr Mwidimi Ndosi, University of Leeds, Leeds

09.55

Cheap as chips and less fattening: Economic evaluation of 'ESCAPE-pain' an integrated rehabilitation programme for chronic knee pain/OA

Prof Michael Hurley, St Georges University of London and Kingston University, London

09.00 – 10.30

Managing the care gap: implementing evidence-based practice in primary care*Chair: Dr Philip Helliwell, University of Leeds, Leeds***Aim:**

To highlight gaps between musculoskeletal research evidence and current primary care practice, updating delegates about the evidence and how the gaps can be addressed

Outcome 1:

Increased knowledge of what current best practice for osteoarthritis, back pain and osteoporosis in primary care should be

Outcome 2:

Understanding of how current clinical practice in primary care differs from the research evidence

Outcome 3:

Awareness of how rheumatologists and general practitioners can work together to address these gaps in care

09.00

Osteoarthritis*Dr Mark Porcheret, Keele University, Keele*

09.30

Mountains, pathways and surfing- implementing best practice for spinal pain*Dr Oliver Hart, Sheffield NHS, Sheffield*

10.00

Falls and fractures in the frail elderly*Prof David Oliver, City University, London*

09.00 – 10.30

Oral abstracts: Adolescent and young adults

09.00

Hypermobility is a risk factor for musculoskeletal pain in adolescence: findings from a prospective cohort study*Dr Jacqui Clinch, Bristol Royal Hospital for Children, Bath*

09.15

The association between gastrointestinal symptoms and the joint hypermobility syndrome in a population of university students*Dr Asma Fikree, Blizard Institute of Cell and Molecular Science, London*

09.30

A comparison of the outcome of adolescent and adult onset systemic lupus erythematosus*Dr Grainne Murphy, University College London, London*

09.45

Anti-NXP2 autoantibody status is a predictor of calcinosis in older but not younger children who develop juvenile dermatomyositis*Dr Sarah Tansley, Royal National Hospital for Rheumatic Diseases, Bath*

10.00

Catch-up growth during Tocilizumab therapy for systemic juvenile idiopathic arthritis (SJIA): tender 2-year data*Speaker to be announced*

10.15

Efficacy and safety of Tocilizumab in polyarticular juvenile idiopathic arthritis (PCJIA): cherish results at week 40*Dr Athimalaipet Ramanan, Bristol Royal Hospital for Children and Royal National Hospital for Rheumatic Diseases, Bath*

09.00 – 10.30

SIG: Education*Chair: Prof Andrew Hassell, Haywood Hospital, Stoke-on-Trent and Keele University School of Medicine, Keele***Aim:**

To promote the development of rheumatology education to patients and health professionals within rheumatology, to develop networks of rheumatology education, to develop collaborative research and development projects within rheumatology

Outcome 1:

For interested participants to progress a national project around the use and development of REMs in undergraduate medical education and to explore its potential in the education of rheumatology nurses and allied health professionals

Outcome 2:

To provide a forum for sharing and developing ideas in the field of education in rheumatology

Outcome 3:

For participants to receive an update on the work of Arthritis ResearchUK in this area, including discussion of the Educators' conference

09.00

Development of a national evaluation of the Regional Evaluation of the Musculoskeletal System (REMS)*Dr David Coady, City Hospital Sunderland Foundation trust, Sunderland*

09.50

An update on Arthritis Research UK education activities*Dr Inam Haq Arthritis Research UK and University of Brighton, Brighton and Mr Keir Windsor Arthritis Research UK, Chesterfield*

09.00 – 10.30

BHPR: Measuring disease activity in psoriatic arthritis

Chairs: Dr Michael Backhouse, University of Leeds, Leeds and Ms Kate Gadsby, Derby Hospitals Foundation Trust, Derby

Aim:

To update delegates on current remission criteria and provide practical experience of disease activity scoring techniques

Outcome 1:

Understand importance of measuring disease activity in the context of modern disease management

Outcome 2:

Gain practical experience of performing joint assessments

09.00

Measurement of disease activity in psoriatic arthritis and minimal disease activity

Dr Laura Coates, University of Leeds, Leeds

09.20

Assessing disease activity: instructions on aspects of minimal disease activity

Dr Laura Coates, University of Leeds, Leeds

09.30

Assessing disease activity workshop on minimal disease activity

Dr Laura Coates, University of Leeds, Leeds, Dr Victoria Chamberlain, Trafford General Hospital, Manchester and Dr David Pickles, Chapel Allerton Hospital, Leeds

10.00

NAPSI: Nail psoriasis severity index

Dr David Pickles, Chapel Allerton Hospital, Leeds

10.15

Interactive quiz

Dr Michael Backhouse, University of Leeds, Leeds

10.30 – 11.30

Poster viewing and exhibition | Tea and coffee**Categories**

BHPR: Audit and clinical evaluation
 BHPR Research: qualitative
 BHPR Research: quantitative
 Biology of bone, cartilage and connective tissue disease
 Education
 Osteoporosis and metabolic bone disease
 Paediatric and adolescent rheumatology
 Pain
 Primary Care
 SLE and antiphospholipid syndrome

Poster Tours

BHPR
 SLE and antiphospholipid syndrome
 Education

10.30 – 11.00

NEW – Innovation theatre: Roche

Combination therapy in RA: Methotrexate debate
Prof Ernest Choy, University of Cardiff, Cardiff

11.00 – 11.30

NEW – Innovation theatre: Medac

Early aggressive use of subcutaneous methotrexate – financial and health benefits
Dr Sandeep Bawa, Gartnavel General Hospital, Glasgow

11.30 – 13.00

Essentials in rheumatology: Symptoms diagnosis and management

Chairs: Prof John Axford, London Rheumatology Clinic, London and Dr Charles Mackworth-Young, Imperial College, London

Aim:

A comprehensive update covering everything you need to know about changes in rheumatology

Outcome 1:

To prepare rheumatologists for revalidation and provide a valuable educational opportunity for trainees

Outcome 2:

Delegates will have had the opportunity to discuss symptom diagnosis

11.30

Bursitis, enthesopathy and nerve entrapment

Dr Andrew Keat, Northick Park Hospital, Harrow

12.00

Autoantibodies

Prof Peter Maddison, Bangor University, Bangor

12.30

Improving patient management: Ready access to biological therapies

Prof Peter Taylor, University of Oxford, Oxford and Sir Andrew Dillon, National Institute for Health and Clinical Excellence, London

11.30 – 13.00

Arthritis pain: mechanisms, meaning and medicines

Chair: Prof David Walsh, University of Nottingham, Nottingham

Aim:

To update on the current understanding of the pathophysiology and psychology of pain in people with arthritis, and recent advances in its medical management

Outcome 1:

Delegates will understand how the relationships between arthritis pain and joint pathology are complex, and how the way that we think about that relationship can have major impact on the development and use of effective analgesics

Outcome 2:

Clinical delegates will reflect on their own practice regarding what explanations they give patients of their pain, and how they should manage it

Outcome 3:

Delegates will be better able to offer advice about medications and exercise, and be aware of novel approaches that may better improve arthritis pain in the near future

11.30

Pathophysiology of arthritis pain peripheral and spinal mechanisms of osteoarthritis pain: experimental models

Prof Victoria Chapman, University of Nottingham, Nottingham

12.00

Why does pain instil fear?

Prof Tamar Pincus, Royal Holloway, University of London, London

12.30

NGF inhibition as a strategy to treat musculoskeletal pain

Dr Dave Shelton, Pfizer Global Research and Development Rinat Laboratories, San Francisco, United States of America

11.30 – 13.00

The emerging role of epigenetics in rheumatic diseases

Chairs: Prof Gerry Wilson, University of Sheffield, Sheffield and Prof Christopher Buckley, University of Birmingham, Birmingham

Aim:

To provide an overview of the role of epigenetics in the pathogenesis of rheumatic diseases

Outcome 1:

To understand the epigenetic mechanisms controlling gene expression

Outcome 2:

To highlight current knowledge on the role of epigenetics in RA and OA

Outcome 3:

To be aware of the potential of therapeutic targeting of the epigenetic signature

11.30

Epigenetic influences in autoimmune rheumatic diseases

Dr Esteban Ballestar, L'Hospitalet de Llobregat, Barcelona, Spain

12.00

The epigenetic influences in osteoarthritis

Prof John Loughlin, University of Newcastle, Newcastle

12.30

Therapeutic targeting of the epigenome

Dr Rabinder Prinjha, Immunoinflammation Therapy Area, GSK Medicines Research, Stevenage

11.30 – 13.00

BHPR plenary orals

- 11.30 Clinical and cost-effectiveness of a multidisciplinary foot care programme for children and adolescents with juvenile idiopathic arthritis: an exploratory trial
Dr Gordon Hendry, University of Western Sydney, Penrith, Australia
- 11.45 Predictors of risk of foot ulceration occurring in people with rheumatoid arthritis (RA) without diabetes
Dr Jill Firth, University of Leeds, Leeds
- 12.00 “I’m being a better doctor”: training for clinicians to support self-management
Dr Emma Dures, Academic Rheumatology, Bristol
- 12.15 Widespread and regional pain predict social participation restriction in older adults: a prospective cohort study
Dr Ross Wilkie, Keele University, Keele
- 12.30 Quality of life over the first 5-years of RA: findings from the early rheumatoid arthritis network
Dr Sam Norton, King’s College London, London
- 12.45 Scottish society of rheumatology (SSR) occupational therapy rheumatoid arthritis (RA) work audit
Mrs Janet Harkess, NHS Fife, Kirkcaldy

11.30 – 13.00

Oral abstracts: Primary care

- 11.30 Transcutaneous electrical nerve stimulation for the management of tennis elbow: a pragmatic randomized controlled trial
Dr Linda Chesterton, Keele University, Keele
- 11.45 Gout is an independent risk factor for all types of vascular disease: a retrospective cohort study in the UK general practice research database (GPRD)
Dr Lorna Clarson, Keele University, Keele
- 12.00 Case-finding for osteoporosis and fracture in primary care
Dr Jane Gibson, NHS Fife, Kirkcaldy
- 12.15 Development of a model consultation and training package for practice nurses to support self-management of patients consulting with osteoarthritis in primary care
Dr Emma Healey, Keele University, Keele
- 12.30 Rocker sole shoes are no more beneficial than flat sole shoes in the management of chronic low back pain
Dr Sian MacRae, King’s College London, London
- 12.45 The risk of a subsequent cancer diagnosis after PMR: a primary care database study
Dr Sara Muller, Keele University, Keele

11.30 – 13.00

SIG: MSK disorders in ethnic minorities

Chair: Prof Kuntal Chakravarty, Queen’s Hospital, Essex

Aim: To understand the metabolism and usefulness of Vitamin D in musculoskeletal disorders with emphasis on ethnic minorities

Outcome 1: To improve the understanding of vitamin D deficiency

Outcome 2: To improve the therapeutic challenges

Outcome 3: To develop research agendas

- 11.30 Vitamin D: its different facets
Dr Trpkovic, Guildford University, Surrey
- 12.00 Research in the vitamin D deficiency in minority population
Prof Mark Johnson, University of Leicester, Leicester
- 12.30 Research in vitamin deficiency
Dr Dipak Dutta, University of Manchester, Manchester

11.30 – 13.00

SIG: Adolescent and young adult rheumatology

Chairs: Dr Alison Jordan, University Hospital Birmingham NHS Foundation Trust, Birmingham and Dr Liza McCann, Alder Hey Children's Hospital, Liverpool

Aim:

To update national clinical and academic picture in transitional rheumatology in key conditions that commence in childhood

Outcome 1:

To gain updates in the increasing evidence supporting the transition of adolescents into adult services. Clinical and psychosocial outcomes

Outcome 2:

To gain understanding in the different viewpoints clinically and academically of adolescent SLE from paediatric and adult experts

Outcome 3:

To update on the pathophysiological understanding and clinical outcomes of adolescents and young adults with MAS/HLH

11.30

Meeting at the edge: a paediatric and adult view of SLE in the adolescent years

Prof David Isenberg, Univerity College London, London, and Dr Michael Beresford, Alder Hey Children's Hospital, Liverpool

12.00

Pathophysiology of teenage/young adult myositis: what have we learnt?

Prof Lucy Wedderburn, University College London, London

12.20

MAS/HLH: current understanding and management in adolescents and young adults

Dr A Ramanan, Bristol Royal Hospital for Children, Bristol

12.50

Adolescent Rheumatology Research Network

Prof Lucy Wedderburn, University College London, London

11.30 – 13.00

SIG: Ultrasound

Chair: Dr Zunaid Karim, Mid Yorkshire NHS Trust, Pontefract

Aim:

To allow for those around the UK with a specialist interest in ultrasound to meet and update each other with regard to training programmes for ultrasound, course developemt and registrar training needs in ultrasound. Delegates will be aware of new developments in BSR ultrasound courses, where they will be held and the agreed outline for future courses

Outcome 1:**Outcome 2:**

Delegates will be informed of results of a questionnaire of rheumatology trainees thoughts on ultrasound training requirements

Outcome 3:

Delegates will have update from specific training programmes in Yorkshire and Scotland

11.30

STR's perspective on ultrasound training needs, food for thought

Dr Rainer Klocke, Dudley NHS Foundation Trust, Dudley

12.00

Developing skills in ultrasound course

Dr Cristina Estrach, University Aintree Hospital NHS Foundation Trust, Liverpool

12.30

Ultrasound anatomy course, new developments and possible future ultrasound injection course

Dr David Wright, City Hospitals Sunderland NHS Foundation Trust, Sunderland

13.00 – 14.00

Exhibition | Lunch

13.00 – 14.00

BSR AGM

Join your colleagues and meet the Trustees, Regional Chairs and committee members of your society. Hear what they have been doing on your behalf and how they plan to meet the challenges of the year ahead. Your attendance is highly valued and tasty lunch bags will be provided.

13.00 – 16.00

Essentials in rheumatology: Clinical decision making

Chairs: Prof John Axford, London Rheumatology Clinic, London and Dr Charles Mackworth-Young, Imperial College, London

Aim:
Outcome 1:
Outcome 2:

A comprehensive update covering everything you need to know about changes in rheumatology
To prepare rheumatologists for revalidation and provide a valuable educational opportunity for trainees
Delegates will have had their clinical decision making skills tested

14.30

Pregnancy

Prof Lesley Regan, Imperial College London, London

15.15

Lupus

Dr David D'Cruz, St Thomas' Hospital, London

13.00 – 16.00

BSR/BHPR: Long-standing musculoskeletal pain: impact, perceptual representations and treatment

Chairs: Dr Nicholas Shenker, Cambridge University Hospitals, Cambridgeshire and Dr Melanie Holden, Arthritis Research UK, Keele University, Keele

Aim:

To provide delegates with an understanding of how long-standing musculoskeletal pain affects both society and the individual and learn how novel approaches have exciting potential in rheumatology

Outcome 1:

Recognise societal impact and disease burden of long-standing musculoskeletal pain

Outcome 2:

Understand how the perceptual representation of the body in pain can impact on function, and how this can be manipulated for therapeutic effect

Outcome 3:

Understand the principles of graded exposure therapy (a psychological/functional approach) and how it may be clinically effective in treating pain

14.30

Musculoskeletal pain - the societal burden

Dr Gareth Jones, University of Aberdeen, Aberdeen

15.00

Musculoskeletal pain - perceptual representations of the painful body

Dr Jenny Lewis, Royal National Hospital for Rheumatic Disease NHS Foundation Trusts, Bath

15.30

Graded exposure in vivo for CRPS-I

Dr Marlies den Hollander, Maastricht University, Maastricht, The Netherlands

14.30 – 16.00

Adolescent and young adult rheumatology

Chairs: Dr Rachel Tattersall, Royal Hallamshire Hospital, Sheffield and Prof Lucy Wedderburn, University College London, London

Aim:

To provide adult rheumatologists and health professionals who care for young adults and/or adolescents with child onset rheumatological conditions with an overview of current best practice in key areas

Outcome 1:

Delegates will have an update on current understanding evidence based on optimal therapeutic management and outcomes of young adults who have arthritis that commenced in childhood

Outcome 2:

Delegates will gain insight into psychosocial impact of JIA on the adolescent and parent and current practice on how to use this knowledge to improve outcomes

Outcome 3:

Delegates will gain updated knowledge concerning the clinical approach of treating adolescents and young adults with childhood onset myositis

14.30

Young adults with child onset arthritis: how our current understanding of the disease and management affect physical and psychosocial outcomes

Dr John Ioannou, University College Hospital, London

14.50

Psychosocial challenges of teenagers/young adults with JIA: can adolescents/young adults be persuaded to 'take the medicine?'

Speaker to be announced

15.10

Psychosocial challenges of teenagers/young adults with JIA: direct and indirect effect of parenting behaviour on older teenagers with JIA – help or hindrance?

Dr Jacqui Clinch, Bristol Royal Hospital for Children, Bath

15.30

How to manage adolescent onset myositis in teenagers and young adults

Dr Clarissa Pilkington, Great Ormond Street Hospital, London

14.30 – 16.00

BHPR: Clinical update on axial spondyloarthritis (ASpA)

Chairs: Mrs Susan Gurden, St Woolos Hospital, Newport and Ms Lindsey Hooper, University of Southampton, Southampton

- Aim:** To provide an overview on current thinking on classification of Inflammatory back pain, recognition, assessment and implementation of treatment, monitoring and management strategies
- Outcome 1:** To discuss issues and uncertainties in diagnostic recognition and onward management of inflammatory back pain
- Outcome 2:** To highlight the implications of psychological status on subjective assessments and awareness of the importance of inter and intra operator reliability when completing BASMI assessment
- Outcome 3:** To introduce the concept and implementation of negotiated monitoring and management strategies, to raise awareness and understanding of specific patient needs within the multidisciplinary team

14.30 **Advances in the diagnosis and management of 'Axial SpA'**

Dr Stefan Siebert, Princess of Wales Hospital, Glasgow

15.00 **Current assessment in ankylosing spondylitis and the importance of a biopsychosocial approach**

Dr Jane Martindale, Wrightington Wigan and Leigh NHS Foundation Trust, Lancashire

15.30 **Ankylosing Spondylitis: personal care plan**

Mr Colin Beevor, Queen Alexandra Hospital, Portsmouth and Ms Claire Jeffries, Queen Alexandra Hospital, Cosham

14.30 – 16.00

Oral abstracts: OA and metabolic bone disease14.30 **Maternal milk intake is associated with increased offspring bone mineral content**

Dr Zoe Cole, MRC Lifecourse Epidemiology Unit, Southampton

14.45 **Bisphosphonate use and improved implant survival: a nation-wide cohort study**

Dr Daniel Prieto-Alhambra, Green Templeton College, Oxford

15.00 **Mortality following elective total hip replacement and hip resurfacing**

Dr Andrew Judge, University of Oxford, Oxford

15.15 **Effect of strontium ranelate on knee pain in osteoarthritis: a responder analysis**

Prof Cyrus Cooper, MRC Lifecourse Epidemiology Unit, Southampton

15.30 **Predictors of poor long-term outcome in physical function following TKA**

Dr Amit Kiran, University of Oxford, Oxford

15.45 **Pegloticase for refractory gout: efficacy and safety summary of the GOUT1 and GOUT2 phase 3 trials**

Dr Faith Ottery, Savient Pharmaceuticals, Inc. New York, United States of America

14.30 – 16.00

ARMA

Chair: Mr Federico Moscogiuri, ARMA, London

- Aim:** Discuss and identify ways to ensure that MSK services reflect local population needs via the development of MSK clinical networks
- Outcome 1:** Present and 'test out' work done by ARMA on clinical networks to date via its strategic partnership with the DH
- Outcome 2:** Identify key challenges in establishing and supporting effective MSK clinical networks
- Outcome 3:** Identify examples of existing good practice and means of disseminating this with key stakeholders and call to action

14.30 **Introduction**

Mr Federico Moscogiuri, ARMA, London

14.40 **The State of musculoskeletal disorders (MSDs) in the NHS**

Dr Chris Deighton, Derby Hospitals NHS Trust, Derby

14.55 **Making it happen: how clinical networks can provide a solution**

Dr Alan Nye, Pennine MSK Partnership Ltd, Oldham

15.10 **Examples of good practice**

Ms Debbie Cook, CEO NASS – National Ankylosing Spondylitis Society, Surrey

15.25 **Interactive panel discussion with question and answer session**

Mr Federico Moscogiuri, ARMA, London

14.30 – 16.00

SIG: SLE

Chair: Prof Ian Bruce University of Manchester, Manchester

Aim:

To learn about the range of neuropsychiatric manifestations associated with SLE and consider how to develop a differential diagnosis and management plan for such patients

Outcome 1:

To understand the range of neuropsychiatric manifestations in SLE

Outcome 2:

To develop a strategy to investigate neuropsychiatric manifestations in SLE patients

Outcome 3:

To learn about management options in patients across the range of neuropsychiatric manifestations in SLE

14.30

An overview of the clinical presentation and manifestations of neuropsychiatric lupus

Prof John G Hanly, Dalhousie University, Halifax, Nova Scotia

14.50

Assessment of neuropsychiatric manifestations of SLE: a neurologist's view point

Dr Michael Zandi, University of Cambridge, Cambridge

15.15

Assessment of neuropsychiatric manifestations of SLE: a psychiatrist's view point

To be announced

15.35

EULAR guidelines on the management of neuropsychiatric manifestations of SLE

Dr George Bertias, University of Crete, Greece

14.30 – 16.00

BHPR: Measuring disease activity in RA, when is your patient in remission

Chair: Dr Michael Backhouse, University of Leeds, Leeds

Aim:

To update delegates on current remission criteria and provide practical experience of disease activity scoring techniques

Outcome 1:

Understand importance of measuring disease activity in the context of modern disease management

Outcome 2:

Gain practical experience of performing joint assessments

Outcome 3:

Update on role of imaging in assessing disease activity

14.30

Why measure disease activity and what should we aim to achieve?

Prof Peter Taylor, University of Oxford, Oxford

14.50

Assessing disease activity: workshop instructions on DAS Scoring

Dr Jill Firth, University of Leeds, Leeds

15.00

Assessing disease activity in RA

Dr Jill Firth, University of Leeds, Leeds, Dr Victoria Chamberlain, Trafford Healthcare NHS Trust, Manchester and Dr David Pickles, Chapel Allerton Hospital, Leeds

15.30

The role of imaging in assessing disease activity

Prof Peter Taylor, University of Oxford, Oxford

15.45

Interactive quiz

Dr Michael Backhouse, University of Leeds, Leeds

16.00 – 16.30

Exhibition | Tea and coffee

16.30 – 17.30

Heberden Oration

The changing face of rheumatoid arthritis: A palindromic shift

Prof Paul Emery, University of Leeds, Leeds

17.30 – 17.45

Industry supported symposia catering

17.45 – 19.30

Industry supported symposia: Abbott

Advances in ultrasound and MRI imaging in rheumatology

Chair: Prof Paul Emery, University of Leeds, Leeds

Aim:

To provide delegates with an overview of the key advances in ultrasound and MR imaging in the management of inflammatory arthritis and update on best practice

Outcome 1:

Delegates will be able understand the key issues in the application of ultrasound in rheumatoid arthritis clinical practice

Outcome 2:

Delegates will be able understand the key issues in the application of magnetic resonance imaging in spondyloarthritis clinical practice

State of the art ultrasound imaging: today and tomorrow

Dr Cristina Estrach, Aintree University Hospital NHS Foundation Trust, Liverpool

A targeted ultrasound approach to remission in RA including TURA study

Prof Paul Emery, University of Leeds, Leeds

Redefining standards of care in SpA with the use of MRI

Dr Alex Bennett, Defence Medical Rehabilitation Centre, Headley Court

19.30 – Late

Conference Dinner

With a lively and diverse culture, Birmingham has a never ending offering of delicious restaurants to try, none better than the popular Shimla Pinks. BSR and BHPR invites guests to carry on networking into the night at this award winning restaurant, enjoy!



07.00 – 07.30

Industry supported symposia catering

07.30 – 08.30

Industry supported symposia: Bristol-Myers Squibb

Getting it right first time – Biologics in RA; a debate

*Chair to be announced***Aim:**

Rheumatologists and allied health professionals managing Rheumatoid Arthritis (RA) have an ever expanding range of treatment options available for the treatment of RA, however it can be challenging to ensure that these therapies are used in a way that offers the best patient outcomes

Outcome 1:

The audience will be able to compare and contrast the differing mechanisms of action and optimal use of biologic therapies in patient-centric treatment of RA

Outcome 2:

The audience will be able to better understand the latest direct head-to-head comparison studies of biologic therapies for the treatment of RA

Outcome 3:

The audience will be able to recognise the impact of choosing appropriate, effective early treatment in order to deliver tight-control on long-term patient outcomes in RA

Current understanding of RA and its aetiology: how can the different MOA's of the biologics be used to deliver patient outcomes?

Prof Peter Taylor, University of Oxford, Oxford

The latest data in the treatment of RA with Biologic therapies: what do the latest head-to-head trials tell us about Biologic Therapies and their place in RA treatment?

Dr Andrew Ostor, Addenbrookes Hospital, Cambridge

What do know, where are we heading – getting it right 1st time, debating the facts

Chairman, speakers and panel

09.00 – 10.30

Ageing and the musculoskeletal system

Chairs: Dr Fraser Birrell, University of Newcastle, Newcastle and Prof Tim Cawston, University of Newcastle, Newcastle

Aim:

The ageing population and high prevalence of age associated musculoskeletal disease make it important that clinicians and researchers keep abreast of the latest research in this field

Outcome 1:

Delegates will understand the concept of healthy ageing

Outcome 2:

Delegates will know the state of the art of work with animal models and stem cells

Outcome 3:

Delegates will recognise the occurrence of age related musculoskeletal disease and the challenges inherent in clinical trials in the elderly

09.00

Musculoskeletal ageing: from epidemiology to clinical trials

Prof Cyrus Cooper, University of Southampton, Southampton

09.30

Mouse models for mechanistic studies of skeletal muscle ageing

Dr Aphrodite Vasilaki, University of Liverpool, Liverpool

10.00

Stem cells and ageing

Dr Illaria Belluantonio, University of Sheffield, Sheffield

09.00 – 10.30

Ask the experts

Chairs: Dr Benjamin Parker, University of Manchester, Manchester and Dr Sonia Panchal, Northampton General Hospital, Northampton

Aim:

To provide trainees with practical teaching and advice on the management of SLE

Outcome 1:

Delegates will be able to present and discuss difficult SLE cases

Outcome 2:

Delegates will have a better understanding of clinical presentation of SLE

Outcome 3:

Delegates will be able to discuss management issues in SLE with an expert panel

09.00

SLE

Prof Ian Bruce, University of Manchester, Manchester and Prof Anisur Rahman, University College, London

09.00 – 10.30

Mortality in rheumatic disease

Chairs: Prof Gary Macfarlane, University of Aberdeen, Aberdeen and Dr Jennifer Hamilton, Queen Elizabeth Hospital, Gateshead

Aim:

To summarise the evidence on whether patients with specific rheumatic diseases experience excess mortality and if so to describe the specific causes of death in excess, possible mechanisms and relevance to management

Outcome 1:

To be able to describe the pattern of mortality associated with three musculoskeletal conditions

Outcome 2:

To understand the mechanisms underlying association with excess mortality

Outcome 3:

To understand the relevance of such patterns of excess mortality for managing patients with specific rheumatic diseases

09.00

Mortality in systemic sclerosis: a European perspective

Prof Ulf Müller-Ladner, Justus-Liebig University Giessen, Bad Nauheim, Germany

09.30

Co-morbidities in RA and their influence on premature mortality

Dr Nicola Gullick, King's College London Hospital, London

10.00

Musculoskeletal pain and excess mortality: the story so far

Dr Kelvin Jordan, Keele University, Keele

09.00 – 10.30

BSR/BHPR: Advanced practice in osteoarthritis

Chairs: Prof Philip Conaghan, University of Leeds, Leeds and Prof Michael Hurley, Kingston University and St George's, University of London, London

Aim:

This multidisciplinary will provide delegates with an overview of how aspects of advanced practice e.g. gait analysis, diagnostic ultrasound can be incorporated into the management pathways for patients with OA

Outcome 1:

Delegates will be able to understand how adverse mechanics influence structure and function at key sites in the lower limb and the implications for OA

Outcome 2:

Delegates will gain an insight into how research and clinical care can be integrated to impact positively on the care of patients with OA pathways for patients with symptomatic OA

Outcome 3:

Delegates will have a better understanding of how mechanical and imaging assessments impact on care

09.00

The assessment of adverse mechanics in knee OA

Prof Martijn Steultjens, Glasgow Caledonian University, Glasgow

09.30

Amsterdam outpatient osteoarthritis clinic: integrating care and science for OA

Dr Martin van der Esch, Reade Rehabilitation Centre, Amsterdam, The Netherlands

10.00

The ULTRASCOT (ULTRASound SCanning of Osteoarthritis in the Thumb) study: results and implications for practice

Mrs Mhairi Brandon, Glasgow Royal Infirmary, Glasgow

09.00 – 10.30

Oral abstracts: RA clinical

09.00

Long-term outcomes of early RA patients initiated with adalimumab plus methotrexate compared with methotrexate alone following a targeted treatment approach

Prof Paul Emery, University of Leeds, Leeds

09.15

24 week results of a blinded phase 2B dose-ranging study of baricitinib, an oral jak1/jak2 inhibitor, in combination with traditional DMARDs in patients with rheumatoid arthritis

Dr Peter Taylor, University of Oxford, Oxford

09.30

Tocilizumab (TCZ) monotherapy compared with adalimumab (ADA) monotherapy in RA: results of a 24 week study

Speaker to be announced

09.45

Head-to-head comparison of subcutaneous abatacept versus adalimumab in the treatment of rheumatoid arthritis: key efficacy and safety results from the ample (abatacept versus adalimumab comparison in biologic-naïve RA subjects with background methotrexate)

Dr Michael Maldonado, Bristol-Myers Squibb, Princeton, United States of America

10.00

What happens to ACPA positive patients without clinical synovitis?

Dr Chadi Rakieh, University of Leeds, Leeds

10.15

Interferon gene expression signature in neutrophils from RA patients pre and post anti-TNF therapy

Dr Helen Wright, University of Liverpool, Liverpool

09.00 – 10.30

SIG: Heritable disorders of connective tissue

Chair: Prof Rodney Grahame, University College Hospital, London and Prof Howard Bird, University of Leeds, Leeds

Aim:

To familiarise BSR and BHPR members and guests with the work of Ehlers-Danlos National Diagnosis Service (funded by the National Commissioning Group) and to assess its progress since its inception in 2010

Outcome 1:

Acquisition of knowledge of the role of molecular genetic testing in the differential diagnosis of the rare forms of EDS

Outcome 2:

Acquisition of knowledge of Novel COL3A1 collagen mutations and their EDS phenotypes

Outcome 3:

Acquisition of knowledge of rheumatological complications in rare genetic syndromes

09.00

New observations on EDS in South Africa

Prof Peter Beighton, University of Cape Town, South Africa

09.15

Novel COL3A1 mutations in Vascular EDS phenotypes (the London experience since 2009)

Prof Mike Pope, Northwick Park and St Marks Hospitals, Harrow

09.30

The EDS National Diagnostic Service in 2013

Dr Glenda Sobey, Sheffield Children's Hospital, Sheffield

09.45

Molecular Genetic Diagnosis in EDS

Dr Mandy Nesbitt, Sheffield Children's Hospital, Sheffield

10.00

Rare Mendelian disorders and Joint Hypermobility Syndrome

Dr Anthony Vandersteen, Northwick Park and St Marks Hospitals, Harrow

10.15

Question and answer session

09.00 – 10.30

SIG: Sjögren's

Chair: Dr Elizabeth Price, Great Western Hospital, Swindon

Aim:

To update and educate rheumatologists on the practical management of and recent advances in Sjögren's syndrome

Outcome 1:

Update management of dry eye in Sjögren's syndrome

Outcome 2:

Update management of dry mouth in Sjögren's syndrome

Outcome 3:

Update on new therapeutic advances in the systemic management of Sjögren's syndrome

09.00

The modern management of dry eye in Sjögren's syndrome

Miss Saaesha Rauz, University of Birmingham, Birmingham

09.25

The modern management of dry mouth in Sjögren's syndrome

Mr John Hamburger, University of Birmingham, Birmingham

09.50

New therapeutic approaches for Sjögren's

Dr Francesca Barone, University of Birmingham, Birmingham

09.00 – 10.30

BHPR: Introducing cognitive behavioural approaches to rheumatic disease: top tips and tools for clinic

Aim:

To introduce rheumatology clinicians to basic cognitive-behavioural CB techniques and tools that can be readily integrated into routine clinical encounters, provide opportunities to observe demonstrations, and for delegates to practice the skills in small groups

Outcome 1:

Learn how to work on a formulation diagram with patients to identify and understand the links between thoughts, feelings and behaviours, and how they relate to symptoms

Outcome 2:

Learn how to support patients to set effective goals by identifying components of SMART goals; including how and where to start, follow up and build on goals, and suggestions for constructive responses when goals are not achieved

Outcome 3:

Learn how to use Socratic questioning to unpick behavior patterns in relation to activity, sleep and rest; and review self-monitoring records with patients to identifying where changes can be made and further support is needed

09.00

Cognitive-behavioural approaches to rheumatic disease: tools for clinic

Dr Emma Dures, Bristol Royal Infirmary, Bristol

09.15

The impact of symptoms: making a cognitive-behavioural formulation

Mrs Elizabeth Hale, Russells Hall Hospital, Dudley and Dr Marianne Morris, University of the West of England, Bristol

09.35

Effective goal setting in the rheumatology clinic

Prof Sarah Hewlett, Bristol Royal Infirmary, Bristol and Dr Claire Goodchild, Institute of Psychiatry, London

09.55

Activity, rest and sleep: understanding behaviour patterns

Dr Nicholas Ambler, Frenchay Hospital, Bristol and Dr Emma Dures, Bristol Royal Infirmary, Bristol

10.30 – 11.30

Poster viewing and exhibition | Tea and Coffee

Categories

Basic Science

Cell receptor-ligand interaction, signalling, activation and apoptosis

Cytokines and inflammatory mediators

Epidemiology

Genetics

Health services research, economics and outcomes research

Miscellaneous rheumatic diseases

Muscle Disorders

Osteoarthritis: clinical features

Osteoarthritis: pathogenesis and animal models

Osteoarthritis: treatment

Scleroderma and related disorders

Sjögren's syndrome and other connective tissue disorders

Soft tissue and regional musculoskeletal disease, fibromyalgia

Spondyloarthropathies (including psoriatic arthritis)

Vasculitis

Poster Tours

Epidemiology

Connective tissue disease

Spondyloarthropathy

10.30 – 11.30

NEW – Innovation theatre: Celgene

Looking inside the cell for a new perspective on psoriatic arthritis

Prof Miles D Houslay, Chair of Pharmacological Innovation, Institute of Pharmaceutical Science, King's College London, London and Prof Oliver Fitzgerald, Newman Clinical Research Professor, School of Medicine and Medical Science, St Vincent's Hospital, Dublin, Ireland

11.30 – 13.00

Oral abstracts: Science

- 11.30 The role of protein kinase D signalling in the induction of matrix metalloproteinases in human articular chondrocytes
Mr Jonathan Baker, University of Newcastle, Newcastle
- 11.45 Effects of PTPN22 R620W on neutrophil function in health and disease
Ms Rachel Bayley, University of Birmingham, Birmingham
- 12.00 Macrophage metabotypes in the hypoxic inflammatory environment assessed using metabolomic profiling
Mr Martin Fitzpatrick, University of Birmingham, Birmingham
- 12.15 Synovial fibroblasts shape the recruitment and migration patterns of lymphocytes during resolving and persistent arthritis
Dr Helen McGettrick, University of Birmingham, Birmingham
- 12.30 Biological roles of C5orf30 in rheumatoid arthritis
Dr Munita Muthana, University of Sheffield, Sheffield
- 12.45 Autocitrullinated porphyromonas gingivalis peptidylarginine deiminase: a novel antigen with potential for breaching immunologic tolerance in rheumatoid arthritis
Dr Anne-Marie Quirke, University of Oxford, Oxford

11.30 – 13.00

Interactive clinical teaching: osteoporosis

Chairs: Dr Benjamin Parker, University of Manchester, Manchester and Dr Sonia Panchal, Northampton General Hospital, Northampton

- Aim:** To provide trainees with up-to-date clinical teaching on osteoporosis
- Outcome 1:** To review pathophysiology of osteoporosis
- Outcome 2:** To review the current evidence base for the treatment of osteoporosis
- Outcome 3:** To review the management of osteoporosis outside of the current evidence base

- 11.30 Osteoporosis: where are we now?
Prof Bill Fraser, University of East Anglia, Norwich
- 12.15 Osteoporosis: what don't we know?
Prof Cyrus Cooper, University of Southampton, Southampton

11.30 – 13.00

Polymyalgia rheumatic and giant cell arthritis

Chair: Dr Colin Pease, Chapel Allerton Hospital, Leeds

- Aim:** Update on diagnosis, investigations, treatment and research advances in PMR and GCA
- Outcome 1:** Apply the recent guidelines for PMR which outline an evaluative process and clues that help differentiate it from other conditions and identify overlap with inflammatory arthritis and large vessel vasculitis. They provide advice on management, goals of treatment and sources for patient education and self-management
- Outcome 2:** Learn about the EULAR ACR classification criteria which outline clinical, laboratory, and ultrasound criteria items for a scoring algorithm for PMR
- Outcome 3:** Learn about imaging studies for PMR and outcome studies to assess disease activity, quality of life and disability
- Outcome 4:** Learn about the status of disease modifying therapies and clinical trials, on-going and in setup, including the use of biological agents and other novel therapies

- 11.30 Classification criteria and guidelines for PMR
Prof Bhaskar Dasgupta, Southend University Hospital, Essex
- 12.00 Polymyalgia rheumatica: the view from primary care
Prof Christian Mallen, Keele University, Keele
- 12.20 Imaging for large vessel vasculitis in PMR and GCA
Prof Justin Mason, Imperial College London, London
- 12.40 Therapy update and clinical trials for PMR
Dr Victor Martinez-Taboada, Santander, Cantabria, Santander - Cantabria, Spain

11.30 – 13.00

Droitwich Lecture and prizes*Chair: Mr Robert Field, President BHPR*

11.30

In defence of non-evidence based medicine*Dr Philip Helliwell, University of Leeds, Leeds*

12.15

Prize ceremony

11.30 – 13.00

Oral abstracts: Genetics

11.30

Musculoskeletal pain is associated with BMI through shared genetic factors*Dr Frances Williams, King's College London, London*

11.45

Estimating heritability of response to treatment with anti-TNF biologic agents using linear mixed models*Dr Darren Plant, University of Manchester, Manchester*

12.00

Genes contributing to pain sensitivity in the normal population: an exome sequencing study*Dr Frances Williams, King's College London, London*

12.15

Ankylosing spondylitis is strongly associated with variants in the CMG2 gene*Ms Tugce Karaderi, University of Oxford, Oxford*

12.30

A pilot study evaluating rna transcription profiles in idiopathic inflammatory and inclusion body myositis: a next generation sequencing approach*Dr Philip Hamann, Royal National Hospital for Rheumatic Diseases, Bath*

12.45

The development of peripheral joint erosions and radiographic sacroiliitis has striking association with certain HLA alleles and haplotypes: genotype-phenotype correlation of 283 consecutive Psoriatic Arthritis patients*Dr Muhammad Haroon, St Vincent's University Hospital, Dublin*

11.30 – 13.00

SIG: Scleroderma*Chair: Prof Christopher Denton, University College London, London***Aim:**

Update on management recommendations for SSc that are being developed and updated via EULAR, UKSSG and BSR. Implications for service provision in UK, shared care and specialist commissioning. Specific review of current best practice approaches to parenchyma

Outcome 1:

Participants will be up-to-date on current status of evidence and expert opinion based recommendations for management of SSc

Outcome 2:

Current best practice management of cardiac disease and lung fibrosis in SSc will be reviewed

Outcome 3:

New methods for objective assessment of Raynaud's phenomenon and digital vascular disease will be presented

11.30

Integrated management recommendations for systemic sclerosis (scleroderma)*Prof Christopher Denton, University College London, London*

11.45

Current approaches to management of lung fibrosis in scleroderma*Dr Bridget Griffiths, Freeman Hospital, Newcastle*

12.10

Assessment and treatment of cardiac involvement*Dr Maya Buch, University of Leeds, Leeds*

12.35

Objective non-invasive assessment of digital vascular disease*Dr Andrea Murray, University of Manchester, Manchester*

11.30 – 13.00

SIG: Soft tissue rheumatism and sports medicine

Chair: Dr Tim Jones, Defence Medical Rehabilitation Centre Headley Court, Surrey

Aim:

To provide a forum for discussion about the diagnosis and treatment of musculoskeletal and sports injuries and the benefits of exercise

Outcome 1:

Presentation on the recent Royal College report into the benefits of exercise in health and disease

Outcome 2:

An overview of the musculoskeletal injuries and conditions commonly found in professional dancers

Outcome 3:

A forum to discuss the future aims and organisation of the SIG in soft tissue rheumatism and sports medicine

11.30

'Exercise for life' The Royal College of Physicians 2012 report and recommendations for physical activity in health and disease

Col John Etherington, Defence Medical Rehabilitation Centre Headley Court, Surrey

12.00

Musculoskeletal injuries in dancers

Dr Roger Wolman, Royal National Orthopaedic Hospital, Stanmore

12.30

Forum to discuss the aims of the SIF in musculoskeletal and sports medicine

Dr Tim Jones, Defence Medical Rehabilitation Centre Headley Court, Surrey

13.00 – 13.30

NEW – Innovation theatre: Abbott

Identifying diagnostic SpA lesions using MRI

Dr Alex Bennett, Defence Medical Rehabilitation Centre Headley Court, Surrey

13.00 – 14.00

Exhibition | Lunch**Categories**

Basic Science

Cell receptor-ligand interaction, signalling, activation and apoptosis

Cytokines and inflammatory mediators

Epidemiology

Genetics

Health services research, economics and outcomes research

Miscellaneous rheumatic diseases

Muscle Disorders

Osteoarthritis: clinical features

Osteoarthritis: pathogenesis and animal models

Osteoarthritis: treatment

Scleroderma and related disorders

Sjögren's syndrome and other connective tissue disorders

Soft tissue and regional musculoskeletal disease, fibromyalgia

Spondylarthropathies (including psoriatic arthritis)

Vasculitis

Poster Tours

Epidemiology

Connective tissue disease

Spondyloarthropathy

13.00 – 14.00

BHPR AGM

Join your colleagues over a buffet lunch and meet BHPR Council members to hear what they have been doing on your behalf and how they plan to meet the challenges of the year ahead. This session follows on from the prestigious Droitwich Lecture and the annual Prize Awards; do stay on to congratulate the deserving prize winners and find out how you can get more involved in BHPR. Your attendance is highly valued.

13.00 – 14.00

RATs AGM

13.00 – 14.00

Standards, Audit and Guidelines working group open meeting**Aim:**

To increase awareness of national audits and new BSR guidelines, promoting clinician engagement

Outcome 1:

Understanding and clinician engagement in the HQIP national audit of rheumatoid and early inflammatory arthritis

Outcome 2:

Awareness of new BSR clinical guidelines to support high quality care

Outcome 3:

Awareness of how to feedback comments on draft guidelines through open consultation

This session will give an overview of activities on guideline development, guideline accreditation and national audits. There will be presentations of new guidelines and the launch of open consultation on these

14.00 – 15.30

Advances in cartilage biology: towards a better understanding of osteoarthritis

Chair: Prof Ian Clarke, University of East Anglia, Norwich

Aim:

To summarise recent advances in cartilage biology relevant to pathogenesis of osteoarthritis

Outcome 1:

Gain insight in novel molecular mechanisms of cartilage damage

Outcome 2:

Understand the importance of stability of the chondrocytes in osteoarthritis progression

Outcome 3:

Understand how homeostatic mechanisms can modify OA outcome and progression and how they could be harnessed for therapy

14.00

Role of injury and alarmins in osteoarthritis

Prof Wim Van den Berg, Radboud University Nijmegen, HC Nijmegen, The Netherlands

14.20

Calcium crystals and Ca++ pathways in the pathogenesis of osteoarthritis

Dr Jessica Bertrand, Muskuloskelettale Medizin, Munster, Germany

14.40

Targeting WNT signalling in osteoarthritis

Dr Francesco Dell'Accio, Queen Mary University of London, London

15.05

FGF signalling integrating biomechanics and cartilage homeostasis

Dr Tonia Vincent, University of Oxford, Oxford

14.00 – 15.30

Career development for new consultants

Chairs: Dr Benjamin Parker, University of Manchester, Manchester and Dr Sonia Panchal, Northampton General Hospital, Northampton

Aim:

To provide trainees with guidance and practical advice on how they may develop their careers as new consultants

Outcome 1:

To discuss the application process for consultant posts

Outcome 2:

To highlight the opportunities available to trainees to develop additional skills pre-CCT

Outcome 3:

Delegates will have a better understanding of the broader role of a new consultant

14.00

How to survive the consultant appointments process - and succeed!

Dr Neil Snowden, North Manchester General Hospital, Manchester

14.30

Becoming a consultant: tips from the front line

Dr Vinodh Devakumar, Royal Oldham Hospital, Oldham

15.00

Becoming a consultant: the extended role

Dr Nicholas Shenker, Addenbrookes Hospital, Cambridge

14.00 – 15.30

Commissioning for rheumatology in a cold climate

Chair: Dr Chris Deighton, Derby Hospital NHS Trust, Derby

Aim:

The NHS reforms for commissioning have been implemented on 1st April 2013. Discuss and identify opportunities and threats for clinical and patient leadership in commissioning services such as rheumatology and how these can shape commissioning in the future plus key practical activities

Outcome 1:

What the key issues are that need to be addressed

Outcome 2:

Identify opportunities for improving patients outcomes and values

Outcome 3:

How can the clinical and patient voice most effectively influence policy and commissioners

Outcome 4:

Identify practical improvements and innovations

14.00

The patient and clinical voice: may the force be with you

Mrs Ailsa Bosworth, NRAS - National Rheumatoid Arthritis Society, Berkshire

14.10

Developing the conditions for commissioning patient pathways that would deliver better value

Prof Paul Corrigan, Director of Strategy and Commissioning of the NHS London Strategic Health Authority, London

14.25

Commissioning clinical services in a cold climate

Mrs Laura Guest, British Society for Rheumatology, London

14.40

Better commissioning for service outcomes practical

Mr Philip Ainsworth, British Society for Rheumatology, London

14.55

Interactive question and answer session

Dr Chris Deighton, Derby Hospitals NHS Trust, Derby

14.00 – 15.30

BHPR: The importance of health literacy in musculoskeletal disease

Chairs: Prof David Scott, Norfolk and Norwich University Hospitals, Norwich and Ms Cathy Ball, Imperial College London, London

Aim:

To provide an overview of the underpinning theory, evidence of effectiveness and strategies to enhance health literacy in patients with musculoskeletal disease

Outcome 1:

Attendees will be able to identify some of the background theories and evidence that contribute to the health literacy field

Outcome 2:

Attendees will have an awareness of the issues contributing to enhancing health literacy and some communication techniques to support these

Outcome 3:

Attendees will be aware of health literacy applications for their own practice

14.00

The evolving concept of health literacy and evidence from a systematic review of accessibility of arthritis patient education

Dr Wendy Lowe, University of Southampton, Southampton and Dr Jo Adams, University of Southampton, Southampton

14.30

The importance of health literacy in doctor patient communication

Dr Joanne Protheroe, Keele University, Keele

14.50

The importance of health literacy in patient engagement in marginalised groups

Prof Ade Adebajo, University of Sheffield, Sheffield and Ms Sandra Robinson, North Tyneside Hospital, Tyne and Wear

14.00 – 15.30

Oral abstracts: Spondyloarthritis

- 14.00 Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial
Prof Ade Adebajo, University of Sheffield, Sheffield
- 14.15 Sustained efficacy of adalimumab in patients with non-radiographic axial spondyloarthritis with positive MRI of the sacroiliac joints or spine or elevated C-reactive protein at baseline
Dr Aileen Pangan, Abbott Laboratories, Illinois, Chicago
- 14.30 Spinal inflammation in the absence of SI joint inflammation on MRI in patients with active non-radiographic axial spondyloarthritis
Dr Aileen Pangan, Abbott Laboratories, Illinois, Chicago
- 14.45 Disease burden is comparable in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis
Speaker to be announced
- 15.00 Effectiveness of sequential biologic use in psoriatic arthritis: results of a large retrospective survey
Dr Meghna Jani, University of Manchester, Manchester
- 15.15 A proposed algorithm and its performance evaluation for the best referral by ophthalmologists of acute anterior uveitis patients with possible underlying spondyloarthropathy
Dr Muhammad Haroon, St Vincent's University Hospital, Dublin

14.00 – 15.30

SIG: Myositis

Chairs: Dr Hector Chinoy Salford Royal NHS Foundation Trust, Salford and Dr Patrick Gordon, Kings College Hospital, London

- Aim:** To provide an update on current issues in myositis and upcoming research/clinical activities
- Outcome 1:** To discuss the latest tools to be used in the diagnosis and differential diagnosis of myositis
- Outcome 2:** To discuss current paradigms in the treatment of inflammatory myositis
- Outcome 3:** To gain an understanding of the extramuscular manifestations in myositis
- 14.00 Development of standards of treatment for adults with myositis and different phenotypes, STAMP
Dr Sarah Tansley, University of Bath, Bath
- 14.20 Summary from the Cochrane review for treatment of myositis
Dr Patrick Gordon, Kings College Hospital, London
- 14.40 Development of new classification criteria in myositis: the international myositis classification criteria project, IMCCP
Dr Hector Chinoy Salford Royal NHS Foundation Trust and Prof Robert Cooper, Salford Royal NHS Foundation Trust, Salford
- 15.05 Challenging myositis patients: case vignettes
Dr Harsha Gunawardena, North Bristol NHS Trust, Bristol

14.00 – 15.30

SIG: Rheumatoid arthritis

Chair: Mrs Janet Cushnaghan, Southampton General Hospital, Southampton

- Aim:** To provide delegates with topics of interest in the field of rheumatoid arthritis
- Outcome 1:** Delegates will increase their knowledge of the reasons for delay in presenting with arthritis symptoms
- Outcome 2:** Delegates will learn about the importance of examining the feet in rheumatoid arthritis
- Outcome 3:** Delegates will be able to participate in discussion around the topics presented
- 14.00 Reasons for delay in presenting with arthritis symptoms
Dr Rebecca Stack, City Hospital, Birmingham
- 14.45 Joint inequalities: should the foot continue to be excluded from the DAS-28?
Dr Lindsay Hooper, Southampton General Hospital, Southampton

14.00 – 15.30

BHPR: The use of ultrasound for nurses and allied health professionals

Chairs: Dr Richard Wakefield, University of Leeds, Leeds and Dr Deborah Turner, Glasgow Caledonian University, Glasgow

Aim:

To provide nurses and allied health professionals AHPs with an overview of the role and clinical benefits of musculoskeletal ultrasound in rheumatology practice

Outcome 1:

Delegates will be able to identify training routes and opportunities to undertake ultrasound training

Outcome 2:

Delegates will be able to identify the benefits of using ultrasound in clinical practice and research to enhance their diagnostic skills

Outcome 3:

Delegates have a better understanding of the treatment opportunities identified using ultrasound

14.00

Training routes for nurses and AHPs in musculoskeletal ultrasound: practical considerations

Dr Catherine Bowen, University of Southampton, Southampton

14.20

The use of ultrasound to support research

Mrs Heidi Siddle, University of Leeds, Leeds

14.40

The use of ultrasonography in a physiotherapy led 'one stop' hand clinic

Mrs Mhairi Brandon, Glasgow Royal Infirmary, Glasgow

15.05

Ultrasound guided injections in rheumatology practice

Mrs Alison Hall, Cannock Chase Hospital, Cannock

16.00 – 15.30

SIG: Genetics

Chair: Prof Anne Barton, University of Manchester, Manchester

Aim:

To understand whether the investment in genetic studies has been worthwhile and what the next steps are to translation to clinical benefit

Outcome 1:

The audience will learn how findings from genetic studies in osteoporosis, osteoarthritis and rheumatoid arthritis have advanced the understanding of the aetiology of those conditions

Outcome 2:

Attendees will appreciate what the next steps are in investigating the loci identified

Outcome 3:

The audience will understand how these findings could impact on clinical practice

16.00

Lessons from genetic fine mapping studies of rheumatoid arthritis

Dr Stephen Eyre, University of Manchester, Manchester

16.30

Lessons from GWAS of osteoarthritis: where do we go from here?

Prof John Loughlin, University of Newcastle, Newcastle

16.55

What have genetic studies of osteoporosis taught us and how can we translate this to the clinic

Prof Stuart Ralston, University of Edinburgh, Edinburgh

16.00 – 17.30

SIG: Osteoarthritis

Chair: Dr Fraser Birrell, University of Newcastle, Newcastle

Aim:

To share progress on the OA trials bank and INBANK projects

Outcome 1:

Know about the Arthritis research UK INBANK project

Outcome 2:

Understand potential benefits from this and the OA trials bank

Outcome 3:

Network with other researchers and discuss research ideas

16.00

Osteoarthritis trials bank update

Prof Michael Doherty, University of Nottingham, Nottingham

16.30

INBANK

Prof George Peat, Keele University, Keele

17.00

Small group discussion

Dr Fraser Birrell, University of Newcastle, Newcastle

16.00 – 17.30

SIG: RA Outcomes

Chair: Dr Adam Young, West Hertfordshire Hospitals NHS Trust, St Albans

Aim:

To explain and explore several recent initiatives in the presentation and management of early adult inflammatory arthritis (AIA)

Outcome 1:

Understanding the need for and likely format and impact of the INBANK hup for AIA

Outcome 2:

How the INBANK AIA hub relates to other important recent and related initiatives like BSR audit and the MRC/ABPI projects, and the NICE assessment programme for biological therapies

Outcome 3:

The impact of these initiatives on both academic and non-academic rheumatology departments in the UK

16.00

Introduction to Early Adult Inflammatory Arthritis (AIA). How can you be involved in several new and exciting national Initiatives

Dr Adam Young, St Albans City Hospital, St Albans

16.10

The ARUK INBANK AIA Hub project: clinical and academic involvement

Prof Ann Morgan, St James' University Hospital, Leeds

16.30

HQIP and BSR audit of RA

Dr Ian Rowe, Worcestershire Acute Hospitals NHS Trust, Worcester

16.50

The MRC Patient Stratification Initiative and Early AIA

Prof Costantino Pitzalis, Barts and The London School of Medicine and Dentistry, London

17.10

BSR NICE negotiations and biologic agents

Dr Chris Deighton, Derby Hospitals NHS Trust, Derby

17.20

Open discussion

16.00 – 17.30

SIG: Vasculitis

Chair: Prof Raashid Luqmani, University of Oxford, Oxford

Aim:

To improve awareness of different forms of vasculitis, to update attendees on the current studies in progress to increase our understanding of the vasculitides, including diagnostic strategies, treatment and outcome

Outcome 1:

To learn more about IgG4 related disease and how it is linked to vasculitis

Outcome 2:

To understand what progress has been made in ongoing and new initiatives in clinical studies and trials in vasculitis

Outcome 3:

To know what role attendees could play in current and future studies in vasculitis

16.00

IgG4 related disease

Dr Emma Culver, University of Oxford, Oxford

16.20

Developing patient-related outcome measures in vasculitis

Dr Joanna Robson, University of Oxford, Oxford

16.40

To be announced

Dr Richard Watts, University of East Anglia, Norwich

17.05

Update on current vasculitis studies in diagnosis and assessment of vasculitis in adults and children.

Brief update on European and other international studies in vasculitis

Prof Raashid Luqmani, University of Oxford, Oxford

16.00 – 17.30

SIG: Interstitial lung disease*Chair: Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead***Aim:**

To share with members the results of the first multi-centre UK study of the outcome of ILD in RA in the biologics era, and develop mechanisms for extending this work into prospective studies. To explore the links between both acute and chronic lung infection in patients with RA and understand the implications for clinical practice

Outcome 1:

To inform everyone of the changing natural history of RA-ILD as seen across the UK through a cohort of over 250 patients drawn from six different centres and to discuss the reasons for the improvement - and the implications for therapy

Outcome 2:

To present results of a major collaborative project exploring the pivotal role of anti-CCP antibody in the development of bronchiectasis in patients both with and without RA - and the implications for future treatment paradigms

Outcome 3:

To review the data on the contribution of acute pulmonary infection to the morbidity and mortality associated with RA, and discuss its implications for our patients. Death from pulmonary disease in its many forms has now overtaken vascular disease as the number one cause of mortality in RA in the UK!

16.00

Welcome and introduction

16.05

ERAS / ERAN experience of lung disease in rheumatoid arthritis*Dr Adam Young, St Albans City Hospital, St Albans*

16.25

UK database on RA-ILD: 25 years of data on predictors, imaging, therapeutics and survival*Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead*

16.45

Interstitial lung disease in rheumatoid arthritis: a chest physician's perspective*Dr Felix Woodhead, Universtiy Hospital, Coventry*

17.05

Bronchiectasis in rheumatoid arthritis: clinical and immunological features*Dr Elizabeth Perry, Arthritis Research UK research fellow, Royal Cornwall Hospital, Truro*

17.25

Group discussion on further priorities for research and education

17.30

End of meeting

Conference REGISTRATION

Please note all prices shown include VAT

Delegate type	One day		Two day		Whole conference	
	*Early	Late	*Early	Late	*Early	Late
BSR Member	£103.20	£150.00	£206.40	£300.00	£263.40	£381.60
BSR non member	£150.00	£217.20	£300.00	£434.40	£381.60	£553.80
BSR RATS	£72.60	£105.00	£145.20	£210.00	£184.80	£267.60
BHPR Member	£67.20	£97.80	£134.40	£195.00	£171.60	£249.00
BHPR non member	£97.80	£141.60	£195.60	£282.60	£223.20	£323.40
**Reduced BSR Member	£90.00	£90.00	£180.00	£180.00	£228.96	£228.96
**Non-clinical scientists/Students	£43.20	£43.20	£86.40	£86.40	£129.60	£129.60
ARMA	£43.20	£43.20	£86.40	£86.40	£129.60	£129.60

* Any registrations received on or before the early bird deadline – Friday 1 February 2013 – will be processed at the early rate.

** To qualify for this rate, please visit the website www.rheumatology.org.uk/registration

Registration package

All registration rates include the following:

- Entry to the scientific session of your choice on the days for which you have registered.
- Entry to the exhibition
- Delegate bag (subject to availability for those registering on site)
- Lunch and refreshments
- Welcome reception (for those registered for Tuesday and/or Wednesday)

Register online now

Registering for **Rheumatology 2013** is easy. Simply visit www.rheumatology.org.uk/registration to book your place at the UK's leading rheumatology event. If you wish to pay for your conference place via invoice, you can request an invoice online. Please note that all registration fees must be paid in full before **23 April 2013**. Online registration closes at **17.00 on Friday 19 April 2013**.

On-site registration

If there are places available, you can register for the conference on-site. Please note that registration rates will be higher on-site as they will include an additional admin fee. We are not able to issue invoices on-site.

Save money, avoid the queues at registration and guarantee your place by booking online now at www.rheumatology.org.uk/conference

Cancellation and amendments

Cancellations received in writing by the BSR events team up until 17.00 on **Friday 22 March 2013**, will be refunded in full minus a £20 cancellation. We regret that we cannot offer refunds for cancellations received after this date, although substitutions may be made, this will incur a £20 administration fee.

Please contact **Lindsay McClenaghan**: lmcclenaghan@rheumatology.org.uk for any registration queries.

Conference HIGHLIGHTS

Essentials in rheumatology

Trainee stream

Allied health professionals

Droitwich Lecture

Primary Care

Basic science

Rheumatology 2013: A HUB OF LEARNING

Networking

Heberden Oration

Heberden Round

Special interest groups

Jewels in the Crown

Industry supported symposia

“Nobody working in rheumatology can afford to miss this excellent meeting”

Join the
CONVERSATION
online



Facebook group:
The British Society for Rheumatology



Linkedin profile name:
BSR Comms



Twitter username:
@Rheumatologyuk

Exhibition

Rheumatology 2013 is the UK's leading exhibition for rheumatology professionals where there is something for everyone: network with your colleagues, share ideas, meet with industry partners and get introduced to our free Innovation Theatre Sessions.

The exhibition will take place in **Hall 3 at the ICC** where you can engage with your industry colleagues and learn about their latest products and services. You are invited to visit the exhibition at the following times:

Tuesday 23 April **08.30 - 17.30**

Wednesday 24 April **08.30 - 17.45**

Thursday 25 April **08.45 - 15.00**

Industry supported symposia

Rheumatology 2013 will once again host the popular industry supported symposia. These educational sessions, scheduled during the conference, are a unique platform to listen to exciting new topics and network.

Sessions will be hosted within the ICC, with a maximum of two symposia running concurrently on the following dates:

Roche

Tuesday 23 April | 17.30- 19.15

Actelion

Wednesday 24 April | 07.30- 08.30

Pfizer

Wednesday 24 April | 07.30- 08.30

Abbott

Wednesday 24 April | 17.30- 19.15

Bristol Myers Squibb

Thursday 25 April | 07.30- 08.30

Exhibitors currently confirmed:

4S Dawn Clinical Software
A. Algeo Ltd
A. Menarini Pharma UK S.R.L
Abbott
Arthritis Research UK
BioMarin
Bristol-Myers Squibb
Celgene Ltd
Central Homecare
GlaxoSmithKline
Hitachi Medical systems UK LTD
IL UK Ltd
Internis Pharma
Medac GmbH
Miltenyi Biotec Ltd
MSD
Optasia Medical
Pfizer
Roche Products Ltd
Savient Pharma Ireland
SOBI
UCB
Wisepress Ltd

For a full list of exhibitors please visit
www.rheumatology.org.uk/engage

NEW Innovation theatre sessions

Rheumatology 2013 is excited to bring to you the new innovation theatre sessions which will add great value to the conference. The Innovation Theatre will be based within the exhibition hall, where 30 minute sessions will take place daily and be hosted by our exhibitors. Sessions will be varied and will include demonstrations.

Sessions will be running on the following dates:

Tuesday 23 April 10.30 and 11.00

Tuesday 23 April 13.00 and 13.30

Wednesday 24 April 10.30 and 11.00

Thursday 25 April 10.30 and 11.00

Thursday 25 April 13.00 and 13.30

Innovation theatre sessions confirmed:

Roche	Tuesday 23 April 11.00 - 11.30
Abbott	Tuesday 23 April 13.00 - 13.30
Savient	Tuesday 23 April 13.30 - 14.00
Roche	Wednesday 24 April 10.30 - 11.00
Medac	Wednesday 24 April 11.00 - 11.30
Celegene	Thursday 25 April 10.30 - 11.00
Abbott	Thursday 25 April 13.00 - 13.30

Please refer to the programme for further details on the Innovation theatre sessions.

Networking OPPORTUNITIES

Alongside the conference in 2013, BSR will be hosting two evening events, providing entertainment and further networking opportunities to our delegates.

Presidents' Reception | Tuesday 23 April 2013

The Presidents of BSR and BHPR, Professor Chris Deighton and Mr Robert Field would like to invite all attendees to join them for an evening of drinks, music and socialising with colleagues. This event is free to all delegates and includes drinks and canapés; a wonderful way to spend your evening in Birmingham and wind down after the first day at **Rheumatology 2013**.

Conference Dinner | Wednesday 24 April 2013

With a lively and diverse culture, Birmingham has a never ending offering of delicious restaurants to try, none better than the popular Shimla Pinks. BSR and BHPR invites guests to carry on networking into the night at the award winning restaurant, enjoying a gourmet Indian feast, socialising and fabulous entertainment along the way, this promises to be an exciting evening.



**Places are limited so
be sure to book early**
Tickets are only £40 (Inc VAT)

For further information please visit www.rheumatology.org.uk/2013socialevents

Join the
CONVERSATION
online



Facebook group:
[The British Society for Rheumatology](#)



Linkedin profile name:
[BSR Comms](#)



Twitter username:
[@Rheumatologyuk](#)



BSR, Bride House, 18-20 Bride Lane, London EC4Y 8EE
Tel: +44 (0) 20 7842 0900 Fax: +44 (0) 20 7842 0901
Website: www.rheumatology.org.uk

A Charity registered in England and Wales
A Company limited by guarantee
VAT No: 404 5637 66
Company Reg. No: 3470316
Charity No: 1067124

